Wolf-Hirschhorn_Syndrome

Genetic MONDO:0008684 Pathograph 27 Chromosomal Disorder

Wolf-Hirschhorn syndrome (WHS) is a contiguous gene deletion disorder caused by hemizygous deletion of the distal short arm of chromosome 4 (4p16.3). Core features are a "Greek warrior helmet" facial gestalt, prenatal-onset growth deficiency, intellectual disability, hypotonia, and seizures (in 90-100% of children). The phenotype reflects haploinsufficiency of multiple genes within the deleted segment, including the histone H3K36 methyltransferase NSD2/WHSC1 (a master regulator of developmental transcription that interacts with Nkx2-5 and other tissue-specific transcription factors), the mitochondrial K+/H+ and Ca2+ exchanger LETM1, the synaptic and neurodevelopmental genes CPLX1, CTBP1 and PIGG, the craniofacial/skeletal regulator MSX1, and the FGF receptor FGFR3. WHS is thus best modeled as a synergistic, multi-gene contiguous deletion disorder rather than a single-gene Mendelian condition.

Ask OpenScientist

Ask a research question about Wolf-Hirschhorn_Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

⚙

Pathophysiology

4p16.3 Contiguous Gene Deletion

Wolf-Hirschhorn syndrome is a contiguous gene deletion disorder caused by hemizygous loss of distal chromosome 4 (4p16.3). Two adjacent "critical regions" lie ~1.8-2.0 Mb from the 4p telomere: WHSCR (a ~165 kb interval encompassing parts of WHSC1/NSD2 and WHSC2/NELFA) and WHSCR-2 (a ~300-600 kb interval that includes the 5' end of WHSC1/NSD2 and all of LETM1). A separate ~197 kb terminal seizure susceptibility region (containing PIGG, ZNF721 and ABCA11P) lies ~368 kb from the 4p telomere. Phenotypic severity scales broadly with deletion size, but individual features track more tightly with which dosage-sensitive genes are removed.

Downstream

NSD2 (WHSC1) Haploinsufficiency Loss of one copy of NSD2/WHSC1 within WHSCR/WHSCR-2 reduces H3K36 dimethyltransferase dosage.

LETM1 Haploinsufficiency and Mitochondrial Ion Dyshomeostasis Loss of LETM1, located in WHSCR-2, halves the mitochondrial K+/H+ and Ca2+/H+ exchanger.

Telomeric 4p Seizure-Susceptibility Region Haploinsufficiency Most WHS deletions extend to the 4p terminus, removing the ~197 kb terminal region containing PIGG and ZNF721.

MSX1 Haploinsufficiency Larger 4p deletions remove MSX1, a craniofacial/odontogenic transcription factor.

FGFR3 Haploinsufficiency FGFR3 lies just distal to the WHS critical regions and is co-deleted in most patients.

Show evidence (4 references)

PMID:32914558 SUPPORT

"The syndrome is caused by deletion of a critical region (Wolf-Hirschhorn Syndrome Critical region-WHSCR) on chromosome 4p16.3."

This establishes the genetic basis of Wolf-Hirschhorn syndrome as a deletion of the critical region on 4p16.3.

PMID:26747863 SUPPORT Human Clinical

"Wolf-Hirschhorn syndrome (WHS) is a contiguous gene deletion syndrome involving variable size deletions of the 4p16.3 region."

Establishes WHS as a contiguous gene deletion syndrome of variable size.

PMID:26747863 PARTIAL Human Clinical

"Two adjacent regions, located approximately 1.8–2.0 Mbp from the 4p terminus, are each proposed to be the minimal region of deletion necessary to observe the core WHS features."

Defines WHSCR/WHSCR-2 as the historically recognized critical regions for the core WHS phenotype.

+ 1 more reference

NSD2 (WHSC1) Haploinsufficiency

NSD2 (also called WHSC1 or MMSET) encodes a SET-domain histone methyltransferase that dimethylates lysine 36 of histone H3 (H3K36me2). NSD2 partners with cell-type-specific transcription factors (e.g., Sall1/Sall4/Nanog in embryonic stem cells, Nkx2-5 in embryonic heart) to deposit H3K36 marks at developmental gene loci, preventing inappropriate transcription. Hemizygous loss of NSD2 is present in essentially all WHS deletions and is considered a major driver of the craniofacial, growth, neurodevelopmental and cardiovascular phenotypes.

chromatin remodeling link ↓ DECREASED regulation of transcription by RNA polymerase II link ↓ DECREASED

histone methyltransferase activity link ↓ DECREASED histone H3K36 dimethyltransferase activity link ↓ DECREASED

Downstream

Impaired H3K36 Dimethylation and Developmental Gene Mis-regulation Reduced NSD2 dosage halves H3K36me2 deposition at developmental gene loci normally co-bound by tissue-specific transcription factors.

Cranial Neural Crest Cell Migration Defect WHSC1/NSD2 is expressed in jaw, face and CNS tissues that depend on cranial neural crest, and its dysregulation has been linked to defective neural crest migration.

Show evidence (3 references)

PMID:25942451 SUPPORT Other

"NSD2 haploinsufficiency causes Wolf-Hirschhorn syndrome"

Cancer-biology review that asserts NSD2 haploinsufficiency as the molecular cause of WHS.

PMID:26092122 SUPPORT Model Organism

"WHSC1 is a histone methyltransferase (HMT) that catalyses the addition of methyl groups to lysine 36 on histone 3. In humans, WHSC1 haploinsufficiency is associated with all known cases of Wolf-Hirschhorn syndrome (WHS)."

Names WHSC1/NSD2 as the histone methyltransferase whose haploinsufficiency underlies WHS.

PMID:19483677 SUPPORT Model Organism

"the H3K36me3-specific histone methyltransferase (HMTase) Wolf-Hirschhorn syndrome candidate 1 (WHSC1, also known as NSD2 or MMSET) functions in transcriptional regulation together with developmental transcription factors whose defects overlap with the human disease Wolf-Hirschhorn syndrome (WHS)"

Identifies WHSC1/NSD2 as the H3K36 methyltransferase that partners with developmental transcription factors implicated in WHS.

Impaired H3K36 Dimethylation and Developmental Gene Mis-regulation

NSD2 normally deposits H3K36me2 at intergenic and gene-body chromatin of euchromatic developmental gene loci. Loss of one functional NSD2 allele reduces global H3K36me2 and impairs co-recruitment of DNMT3A and other readers, blunting transcription of developmental targets that NSD2 co-regulates with cell-type-specific transcription factors such as Nkx2-5 in the embryonic heart. In Whsc1-deficient mice, this leads to growth retardation and a constellation of WHS-like midline defects, including congenital cardiovascular anomalies, that are aggravated by Nkx2-5 heterozygosity. Zebrafish DrWhsc1 morphants similarly fail to dimethylate H3K36 and develop endbrain enlargement, abnormal cartilage, reduced bone and incomplete motor neuron formation.

regulation of transcription by RNA polymerase II link ↕ DYSREGULATED chromatin remodeling link ↓ DECREASED

histone H3K36 dimethyltransferase activity link ↓ DECREASED

Downstream

Severe Delayed Psychomotor Development Loss of H3K36me2 at neurodevelopmental target genes contributes to brain developmental delay.

Intellectual Disability Mis-regulation of neuronal differentiation/transcription programs contributes to cognitive impairment.

Intrauterine Growth Retardation Whsc1-deficient mice show growth retardation phenocopying prenatal growth deficiency in WHS.

Postnatal Growth Retardation Persistent NSD2-dependent transcriptional defects underlie ongoing growth failure after birth.

Congenital Heart Defects Failure to deposit H3K36me at Nkx2-5 cardiac targets disrupts outflow tract and septal development.

Skeletal Anomalies Reduced H3K36me2 at osteochondral developmental loci impairs cartilage and bone formation.

Show evidence (4 references)

PMID:19483677 SUPPORT Model Organism

"Whsc1-deficient mice showed growth retardation and various WHS-like midline defects, including congenital cardiovascular anomalies."

Mouse Whsc1 deficiency recapitulates growth retardation and midline/cardiac defects of WHS.

PMID:19483677 SUPPORT Model Organism

"The effects of Whsc1 haploinsufficiency were increased in Nkx2-5 heterozygous mutant hearts, indicating their functional link."

Establishes the NSD2/WHSC1-Nkx2-5 transcriptional axis as a driver of WHS cardiac phenotypes.

PMID:20946879 SUPPORT Model Organism

"Morpholino oligonucleotides for the DrWhsc1 gene affected early embryogenesis in zebrafish, such as endbrain enlargement, abnormal cartilage, marked reduction of bone, and incomplete motor neuron formation."

Zebrafish Whsc1 knockdown produces brain, skeletal and motor neuron phenotypes that mirror WHS features.

+ 1 more reference

LETM1 Haploinsufficiency and Mitochondrial Ion Dyshomeostasis

LETM1 lies in WHSCR-2 and encodes an inner-mitochondrial-membrane protein that catalyses K+/H+ exchange and Ca2+/H+ antiport, and controls mitochondrial volume, membrane potential and OXPHOS protein integrity. Hemizygous loss in WHS halves LETM1 dosage, producing impaired mitochondrial K+ efflux, perturbed Ca2+ handling, lower brain ATP and increased seizure susceptibility in mouse models. LETM1 has long been treated as the major candidate gene for WHS-associated seizures, although patients with deletions sparing LETM1 can still have seizures, indicating that LETM1 haploinsufficiency is necessary but not sufficient.

mitochondrial calcium ion homeostasis link ↓ DECREASED potassium ion homeostasis link ↓ DECREASED

mitochondrial inner membrane link

Downstream

Seizures Mitochondrial K+/H+ and Ca2+ dyshomeostasis with reduced brain ATP lowers neuronal seizure threshold.

Hypotonia Mitochondrial bioenergetic deficit affects skeletal-muscle and neuromuscular tone.

Show evidence (4 references)

PMID:24738919 SUPPORT Human Clinical

"LETM1, encoding a mitochondrial protein playing a role in K(+) /H(+) exchange and in Ca(2+) homeostasis, is currently considered the major candidate gene."

Establishes LETM1 as the historically major candidate gene for WHS seizures and its mitochondrial K+/H+ and Ca2+ functions.

PMID:36055214 SUPPORT Human Clinical

"Leucine zipper-EF-hand containing transmembrane protein 1 (LETM1) encodes an inner mitochondrial membrane protein with an osmoregulatory function controlling mitochondrial volume and ion homeostasis."

Defines LETM1's molecular function as the inner-mitochondrial-membrane osmoregulator.

PMID:36055214 PARTIAL Human Clinical

"bi-allelic LETM1 variants are associated with defective mitochondrial K+ efflux, swollen mitochondrial matrix structures, and loss of important mitochondrial oxidative phosphorylation protein components"

Bi-allelic loss-of-function LETM1 variants confirm the cellular consequences of LETM1 loss that are partially recapitulated in WHS heterozygotes.

+ 1 more reference

Telomeric 4p Seizure-Susceptibility Region Haploinsufficiency

High-resolution chromosomal microarray mapping (n=48) refined an independent seizure-susceptibility region to a ~197 kb interval starting ~368 kb from the 4p telomere, distal to LETM1 and containing PIGG, ZNF721 and the pseudogene ABCA11P. Patients with interstitial deletions whose distal breakpoint preserves the terminal 751 kb (and thus this region) lack seizures, while all patients whose deletions include this region have seizures, even when LETM1 is deleted. Network analysis of WHS seizure cohorts shows that PIGG, CPLX1, CTBP1 and LETM1 act through partially overlapping mechanisms converging on impaired neuronal communication, supporting a synergistic-haploinsufficiency model.

PIGG link CPLX1 link CTBP1 link

chemical synaptic transmission link ↓ DECREASED synaptic vesicle exocytosis link ↓ DECREASED trans-synaptic signaling link ↓ DECREASED

Downstream

Seizures Synergistic haploinsufficiency of PIGG, CPLX1, CTBP1 and LETM1 disrupts neuronal communication and lowers seizure threshold.

Show evidence (4 references)

PMID:26747863 SUPPORT Human Clinical

"We identify a small terminal region of chromosome 4p that represents a seizure susceptibility region. Deletion of this region in the context of WHS is sufficient for seizure occurrence."

Defines the terminal 4p seizure-susceptibility region whose deletion is sufficient for WHS-associated seizures.

PMID:26747863 PARTIAL Human Clinical

"Some of these deletions suggest that LETM1 deletion is neither necessary nor sufficient for the expression of a seizure phenotype in individuals with WHS"

Refutes a single-gene LETM1 model and motivates the search for additional seizure-susceptibility genes.

PMID:24738919 SUPPORT Human Clinical

"haploinsufficiency not limited to LETM1 but including other genes acts as a risk factor for the WHS-associated seizure disorder, according to a comorbidity model of pathogenesis"

Supports a comorbidity/synergistic model of WHS seizures involving LETM1 and additional genes.

+ 1 more reference

Cranial Neural Crest Cell Migration Defect

Most of the WHS-affected midline structures (Greek-warrior-helmet facies, palatal clefts, cardiac outflow tract, mandibular and auricular cartilage, dental papilla) derive from cranial neural crest cells. Multiple WHS-region genes (NSD2/WHSC1, LETM1, TACC3, FGFR3) are enriched in migratory neural crest, and their combined haploinsufficiency is proposed to perturb neural crest cell motility, epithelial-to-mesenchymal transition (via NSD2-Twist regulation) and chemotactic responses to FGF8 (via FGFR1/3). The result is reduced delivery and patterning of neural crest derivatives at the face, ear, jaw and conotruncal heart.

migratory neural crest cell link migratory cardiac neural crest cell link

neural crest cell migration link ↓ DECREASED

cranial neural crest link embryonic head link

Downstream

Characteristic Facial Features Defective migration of cranial neural crest into the frontonasal and maxillary processes shapes the Greek-warrior-helmet facies.

Hypertelorism Aberrant cranial-neural-crest patterning of midfacial structures contributes to widely spaced eyes.

Cleft Lip or Palate Disrupted neural crest delivery to the palatal shelves contributes to midline cleft.

Congenital Heart Defects Reduced cardiac neural crest migration into the outflow tract contributes to septal and conotruncal defects.

Show evidence (2 references)

PMID:27777068 SUPPORT Other

"we propose a novel characterization for WHS as a pathophysiology owing in part to defects in neural crest cell motility and migration during development."

Review proposes defective cranial neural crest migration as a unifying mechanism for WHS midline phenotypes.

PMID:27777068 SUPPORT Other

"the formation of structures of the face and jaw, as well as certain glial cell populations in the brain, depend on neural crest cell migration"

Establishes the developmental dependence of WHS-affected craniofacial structures on cranial neural crest migration.

FGFR3 Haploinsufficiency

FGFR3 lies just distal to the WHSC1/LETM1 critical regions in 4p16.3 and is co-deleted in most WHS patients. FGFR3 normally inhibits chondrocyte proliferation and supports inner-ear cochlear hair cell development; together with FGFR1, FGFR3 also mediates cardiac neural-crest chemotaxis to FGF8. Loss of one copy contributes to skeletal anomalies and to inner-ear and conductive hearing abnormalities. Whsc1-deficient mice show cochlear hair-cell stereocilia defects that recapitulate WHS sensorineural hearing loss, identifying NSD2 as a complementary contributor at the cochlear level.

chondrocyte link auditory hair cell link

fibroblast growth factor receptor signaling pathway link ↓ DECREASED

internal ear link skeletal system link

Downstream

Skeletal Anomalies Reduced FGFR3 signaling alters chondrocyte regulation and skeletal patterning.

Sensorineural Hearing Loss Defective cochlear hair-bundle maturation impairs sound transduction.

Show evidence (2 references)

PMID:26092122 SUPPORT Model Organism

"WHSC1-deficient mice display craniofacial defects that overlap with WHS, including cochlea anomalies. Although auditory hair cells are specified normally, their stereocilia hair bundles required for sound perception fail to develop the appropriate morphology."

Whsc1-deficient mice phenocopy WHS sensorineural hearing loss via cochlear hair-bundle defects.

PMID:27777068 PARTIAL Other

"FGFRs 1 and 3 have recently been implicated in the chemotactic response of cardiac neural crest cells to FGF8 in the pharyngeal ecto-and endoderm in chick embryos, operating upstream of the MAPK/ERK pathway"

Provides mechanism by which FGFR3 haploinsufficiency may compromise cardiac neural-crest chemotaxis.

MSX1 Haploinsufficiency

Larger 4p deletions extend proximally to encompass MSX1, a homeobox transcription factor essential for tooth-bud and palatal-shelf development. Heterozygous loss of MSX1 causes non-syndromic tooth agenesis and orofacial clefts on its own; in WHS its haploinsufficiency is proposed to contribute to hypodontia, abnormal tooth morphology and cleft-palate susceptibility, on top of the broader cranial neural-crest dysfunction.

odontoblast link

odontogenesis link ↕ DYSREGULATED

Downstream

Tooth Abnormalities MSX1 haploinsufficiency disrupts tooth-bud induction, contributing to hypodontia and abnormal dental morphology in WHS.

Cleft Lip or Palate MSX1 dosage is required for palatal-shelf fusion; its loss contributes to cleft palate risk in larger 4p deletions.

Show evidence (1 reference)

PMID:29628999 PARTIAL Human Clinical

"Mutation of candidate genes PAX9 and MSX1 have been identified as the main causes of hypodontia and oligodontia"

Identifies MSX1 as a primary disease gene for tooth agenesis. Evidence is extrapolated from non-syndromic tooth agenesis literature; no WHS-specific MSX1 publication is cited here.

NSD2-Dependent B-cell Maturation Defect

Beyond its roles in development, NSD2/WHSC1 is required in B lymphocytes for class-switch recombination and B1-cell development. NSD2 haploinsufficiency in WHS therefore plausibly contributes to the humoral immunodeficiency (low IgM/IgG3/IgA, hypogammaglobulinemia) that has been documented in a subset of WHS patients and that underpins their susceptibility to recurrent infections.

B cell link

histone H3K36 dimethyltransferase activity link ↓ DECREASED

Downstream

Immunodeficiency NSD2-dependent B-cell class switching and B1 lineage defects can contribute to humoral immune impairment in WHS.

Show evidence (2 references)

PMID:32862441 SUPPORT Model Organism

"NSD2 is required for B cell class switch recombination"

NSD2 is required for normal B-cell class switching, providing a mechanism for WHS-associated humoral immunodeficiency.

PMID:32862441 PARTIAL Model Organism

"deletion of the catalytic domain of NSD2 in primary B cells impairs the generation of B1 lineage. Thus, NSD2, a histone H3 K36 dimethylase, is the first-in-class epigenetic regulator of a B-cell lineage in mice."

NSD2 SET-domain loss in mouse B cells impairs B1 cell development.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Cardiovascular 1

Congenital Heart Defects FREQUENT Abnormal heart morphology (HP:0001627)

Congenital heart defects occur in a substantial proportion of patients.

Show evidence (2 references)

PMID:29199884 SUPPORT

"Wolf-Hirschhorn syndrome is a rare genetic syndrome caused by a heterozygous deletion on chromosome 4p16.3 and is characterized by a "Greek warrior helmet" facies, hypotonia, developmental delay, seizures, structural central nervous system defects, intrauterine growth restriction, sketelal..."

This identifies cardiac defects as one of the characteristic features of Wolf-Hirschhorn syndrome.

PMID:33599186 SUPPORT

"The infant had multiple congenital anomalies; a cleft palate, microcephalia, micrognathia, renal pelvicalyceal ectasia, atrial septal defect, transvers arcus hypoplasia, patent ductus arteriosus, hypospadias and undescended testicle."

This case report documents specific cardiac defects (atrial septal defect, patent ductus arteriosus) in Wolf-Hirschhorn syndrome.

Digestive 1

Feeding Difficulties FREQUENT Feeding difficulties (HP:0011968)

Feeding difficulties are highly variable but commonly recognized in WHS, frequently requiring special feeding techniques, gavage feeding or gastrostomy, and contributing to postnatal growth failure.

Show evidence (1 reference)

PMID:26747863 SUPPORT Human Clinical

"additional highly variable clinical features of WHS include, but are not limited to, feeding difficulties, congenital heart defects, hearing loss, skeletal anomalies, kidney and urinary tract malformations, and ophthalmological and dental abnormalities."

WHS clinical-genetic literature lists feeding difficulties among the recurrent variable features.

Ear 1

Sensorineural Hearing Loss OCCASIONAL Sensorineural hearing impairment (HP:0000407)

Sensorineural hearing loss is reported in approximately 15% of WHS patients and is attributable to cochlear hair-cell defects in NSD2-deficient and FGFR3-deficient cochleas. (Overall hearing loss in WHS, predominantly conductive, occurs in >40% of patients but is captured separately by the Abnormality of hearing parent term.)

Show evidence (1 reference)

PMID:26092122 SUPPORT Model Organism

"The cardinal feature of WHS is a craniofacial dysmorphism, which is accompanied by sensorineural hearing loss in 15% of individuals with WHS."

Establishes sensorineural hearing loss as occurring in approximately 15% of WHS patients with a cochlear-hair-cell origin.

Eye 1

Hypertelorism VERY_FREQUENT Hypertelorism (HP:0000316)

Widely spaced eyes are a characteristic feature contributing to the distinctive facial appearance.

Show evidence (2 references)

PMID:9774859 SUPPORT

"At the autopsy, the propositus showed microcephaly, prominent glabella, broad bridge of the nose, ocular hypertelorism, poorly differentiated and low-set ears, bilateral palatoschisis, and micrognathia."

This case report confirms ocular hypertelorism as a characteristic craniofacial feature of Wolf-Hirschhorn syndrome.

PMID:29199884 SUPPORT

"Ocular findings included normal intraocular pressures and corneal diameters, large-angle exotropia, downward slanting of the palpebral fissures, absent eyelid creases, upper and lower eyelid retraction with shortage of the anterior eyelid lamellae, euryblepharon, lagophthalmos with poor Bell's..."

This documents hypertelorism as one of the ocular findings in Wolf-Hirschhorn syndrome.

Genitourinary 1

Renal Anomalies FREQUENT Abnormality of the kidney (HP:0000077)

Renal/urological anomalies including renal hypoplasia and oligomeganephronia occur in roughly half of WHS patients, particularly with larger 4p deletions, and warrant routine renal surveillance.

Show evidence (3 references)

PMID:34572183 PARTIAL

"In some cases, we observed seizures, structural brain abnormalities, immunodeficiencies, and renal anomalies."

This study identifies renal anomalies as a manifestation in some cases of Wolf-Hirschhorn syndrome.

PMID:41225980 SUPPORT

"It is characterized by intrauterine growth restriction (IUGR), developmental delay, epilepsy, distinctive facial features, and urinary tract anomalies, particularly renal hypoplasia."

This identifies renal hypoplasia as a characteristic urinary tract anomaly in Wolf-Hirschhorn syndrome.

PMID:29199884 SUPPORT

"Systemic findings included "Greek warrior helmet" facies, hypotonia, cleft palate, neonatal tooth eruption, talipes equinovarus, bilateral clinodactyly, clitoromegaly, partial agenesis of the corpus callosum, bilateral renal hypoplasia, and two atrial septal defects."

This case report documents bilateral renal hypoplasia as a systemic finding in Wolf-Hirschhorn syndrome.

Head and Neck 4

Characteristic Facial Features VERY_FREQUENT Abnormal facial shape (HP:0001999)

The distinctive facies includes broad nasal bridge continuing to the forehead (Greek warrior helmet appearance), microcephaly, high forehead with prominent glabella, hypertelorism, and micrognathia.

Show evidence (2 references)

PMID:25137600 SUPPORT

"The major features of this disorder include a characteristic facial appearance known as the "Greek helmet," delayed growth and development; prenatally and postnatally, intellectual disabilities, and seizures."

This establishes the characteristic Greek helmet facial appearance as a major diagnostic feature.

PMID:32914558 SUPPORT

"Its core features are typical facial gestalt, growth retardation, intellectual disability, or developmental delay and seizures."

This identifies the typical facial gestalt as one of the core features of Wolf-Hirschhorn syndrome.

Microcephaly VERY_FREQUENT Microcephaly (HP:0000252)

Small head circumference is a consistent feature of Wolf-Hirschhorn syndrome.

Show evidence (1 reference)

PMID:18474167 SUPPORT

"It was characterized by well-described facial appearance, seizures, microcephaly and midline closure defects along with growth and mental retardation."

This establishes microcephaly as a characteristic feature of Wolf-Hirschhorn syndrome.

Cleft Lip or Palate OCCASIONAL Cleft palate (HP:0000175)

Cleft lip/palate may occur in some cases.

Show evidence (1 reference)

PMID:33599186 SUPPORT

This case report documents cleft palate as one of the congenital anomalies in Wolf-Hirschhorn syndrome.

Tooth Abnormalities FREQUENT Abnormality of the dentition (HP:0000164)

Dental abnormalities including hypodontia, abnormal tooth morphology, delayed eruption and neonatal teeth are recurrent in WHS, consistent with co-deletion of MSX1 in larger 4p deletions and broader cranial neural-crest dysfunction.

Show evidence (2 references)

PMID:29199884 SUPPORT

Lists abnormal tooth development among the characteristic WHS features.

PMID:29199884 PARTIAL

Documents neonatal tooth eruption as a specific dental abnormality observed in WHS.

Immune 1

Immunodeficiency OCCASIONAL Immunodeficiency (HP:0002721)

Immunodeficiencies have been observed in some cases and should be looked for.

Show evidence (1 reference)

PMID:34572183 SUPPORT

"In some cases, we observed seizures, structural brain abnormalities, immunodeficiencies, and renal anomalies."

This study identifies immunodeficiencies as a rare manifestation that should be looked for in Wolf-Hirschhorn syndrome.

Musculoskeletal 2

Hypotonia VERY_FREQUENT Hypotonia (HP:0001252)

Hypotonia with muscle underdevelopment is a characteristic feature.

Show evidence (1 reference)

PMID:29199884 SUPPORT

This establishes hypotonia as one of the characteristic features of Wolf-Hirschhorn syndrome.

Skeletal Anomalies FREQUENT Abnormality of the skeletal system (HP:0000924)

Skeletal anomalies may include kyphosis, scoliosis, vertebral malformations, and limb abnormalities.

Show evidence (2 references)

PMID:29199884 SUPPORT

This identifies skeletal anomalies as one of the characteristic features of Wolf-Hirschhorn syndrome.

PMID:9774859 SUPPORT

"Midline closure defects of the cervical spine bodies, lower jaw, and skull base were seen at postmortem radiography."

This case report documents specific skeletal abnormalities including cervical spine defects in Wolf-Hirschhorn syndrome.

Nervous System 4

Intellectual Disability VERY_FREQUENT Intellectual disability (HP:0001249)

Intellectual disability is moderate to severe in most cases, rarely mild.

Show evidence (3 references)

PMID:32914558 SUPPORT

"Its core features are typical facial gestalt, growth retardation, intellectual disability, or developmental delay and seizures."

This identifies intellectual disability as one of the core features of Wolf-Hirschhorn syndrome.

PMID:25137600 SUPPORT

This establishes intellectual disabilities as a major feature of the disorder.

PMID:18474167 SUPPORT

"It was characterized by well-described facial appearance, seizures, microcephaly and midline closure defects along with growth and mental retardation."

This confirms mental retardation (intellectual disability) as a characteristic feature.

Severe Delayed Psychomotor Development VERY_FREQUENT Global developmental delay (HP:0001263)

Severe developmental delays affecting motor skills, speech, and adaptive functioning.

Show evidence (2 references)

PMID:29199884 SUPPORT

This identifies developmental delay as one of the characteristic features of Wolf-Hirschhorn syndrome.

PMID:40404199 PARTIAL

"Wolf-Hirschhorn syndrome (WHS) is associated with intellectual disability and multiple congenital anomalies."

This confirms the association of Wolf-Hirschhorn syndrome with intellectual disability and developmental impairment.

Seizures VERY_FREQUENT Seizure (HP:0001250)

Seizures are a very frequent feature, occurring in the majority of patients with Wolf-Hirschhorn syndrome.

Show evidence (3 references)

PMID:32914558 SUPPORT

"Its core features are typical facial gestalt, growth retardation, intellectual disability, or developmental delay and seizures."

This identifies seizures as one of the core features of Wolf-Hirschhorn syndrome.

PMID:25137600 SUPPORT

This establishes seizures as a major feature of the disorder.

PMID:18474167 SUPPORT

"It was characterized by well-described facial appearance, seizures, microcephaly and midline closure defects along with growth and mental retardation."

This confirms seizures as a characteristic feature of Wolf-Hirschhorn syndrome.

Corpus Callosum Abnormalities OCCASIONAL Abnormal corpus callosum morphology (HP:0001273)

Structural central nervous system defects including corpus callosum abnormalities may occur.

Show evidence (2 references)

PMID:29199884 SUPPORT

This case report documents partial agenesis of the corpus callosum as a structural CNS abnormality in Wolf-Hirschhorn syndrome.

PMID:34572183 PARTIAL

"In some cases, we observed seizures, structural brain abnormalities, immunodeficiencies, and renal anomalies."

This study identifies structural brain abnormalities as a manifestation in some cases of Wolf-Hirschhorn syndrome.

Growth 2

Intrauterine Growth Retardation VERY_FREQUENT Intrauterine growth retardation (HP:0001511)

Marked intrauterine growth retardation is a consistent prenatal finding in Wolf-Hirschhorn syndrome.

Show evidence (1 reference)

PMID:25137600 SUPPORT

This describes delayed growth and development both prenatally and postnatally as major features.

Postnatal Growth Retardation VERY_FREQUENT Postnatal growth retardation (HP:0008897)

Slow postnatal weight gain and continued growth impairment are characteristic.

Show evidence (1 reference)

PMID:30289612 SUPPORT

"Wolf-Hirschhorn syndrome (WHS) is a rare contiguous gene deletion disorder characterized by distinctive craniofacial features, prenatal/postnatal growth deficiency, intellectual disability, and seizures."

This establishes prenatal/postnatal growth deficiency as a characteristic feature of Wolf-Hirschhorn syndrome.

Other 1

Status Epilepticus FREQUENT Status epilepticus (HP:0002133)

Status epilepticus is a frequent and clinically significant complication of WHS-associated epilepsy, occurring in roughly 58% of patients in pediatric cohorts and contributing to neurological morbidity.

Show evidence (1 reference)

PMID:41303083 SUPPORT Human Clinical

"Status epilepticus occurred in 58% of cases, with a high proportion requiring multiple ASMs."

Pediatric WHS cohort directly quantifies status epilepticus prevalence at 58%.

🧬

Genetic Associations

Chromosome 4p16.3 Deletion (Causal)

Show evidence (2 references)

PMID:32914558 PARTIAL

"Less than half of the patients can be identified by conventional cytogenetics and molecular cytogenetic testing should be offered for diagnosis. Karyotyping of the parents should always be offered in a child with WHS."

This provides important diagnostic guidance regarding the need for molecular cytogenetic testing and parental karyotyping.

PMID:11584045 SUPPORT Human Clinical

"Cases with large de novo deletions (proximal to and including p15.2) were more likely to have died than those with smaller deletions (odds ratio=5.7, 95% CI=1.7-19.9) after adjusting for age."

Larger 4p deletions carry a 5.7-fold increased mortality, consistent with the contiguous-gene-deletion model where more haploinsufficient genes drive worse outcomes.

NSD2 (WHSC1) Haploinsufficiency (Causal)

Show evidence (1 reference)

PMID:25942451 SUPPORT Other

"NSD2 haploinsufficiency causes Wolf-Hirschhorn syndrome"

Cancer-biology review naming NSD2 haploinsufficiency as a cause of WHS.

LETM1 Haploinsufficiency (Contributory)

Show evidence (1 reference)

PMID:24738919 SUPPORT Human Clinical

"LETM1, encoding a mitochondrial protein playing a role in K(+) /H(+) exchange and in Ca(2+) homeostasis, is currently considered the major candidate gene."

Establishes LETM1 as the historical major candidate seizure gene.

PIGG Haploinsufficiency (Contributory)

Show evidence (1 reference)

PMID:26747863 SUPPORT Human Clinical

"We identify a small terminal region of chromosome 4p that represents a seizure susceptibility region. Deletion of this region in the context of WHS is sufficient for seizure occurrence."

PIGG (within the terminal seizure-susceptibility region) contributes to the WHS seizure phenotype.

CPLX1 Haploinsufficiency (Contributory)

Show evidence (1 reference)

PMID:35278209 SUPPORT Computational

"The proximity among the previous reported haploinsufficient candidate genes (PIGG, CPLX1, CTBP1, LETM1) and disease genes associated with epilepsy suggests not just one, but different impaired mechanisms in cellular networks responsible for the balance of neuronal activity in WHS patients, from..."

Network analysis groups CPLX1 with PIGG/CTBP1/LETM1 as a synergistic seizure-susceptibility module.

CTBP1 Haploinsufficiency (Contributory)

Show evidence (1 reference)

PMID:35278209 PARTIAL Computational

"CTBP1 obtained the largest number of drug associations, reinforcing its importance for adaptations of brain circuits and its putative use as a pharmacological target for treating seizures/epilepsy in patients with WHS."

Identifies CTBP1 as a candidate drug-targetable haploinsufficient gene in WHS.

FGFR3 Haploinsufficiency (Contributory)

Show evidence (1 reference)

PMID:27777068 PARTIAL Other

FGFR3 haploinsufficiency may compromise cardiac neural-crest chemotaxis upstream of MAPK/ERK.

MSX1 Haploinsufficiency (Contributory)

Show evidence (1 reference)

PMID:29628999 PARTIAL Human Clinical

"Mutation of candidate genes PAX9 and MSX1 have been identified as the main causes of hypodontia and oligodontia"

Identifies MSX1 as a primary tooth-agenesis disease gene; mechanistic role in WHS dental phenotypes is extrapolated from this non-syndromic literature.

💊

Treatments

Seizure Management with Levetiracetam

Action: Pharmacotherapy NCIT:C15986

Agent: levetiracetam ↗

Levetiracetam has shown efficacy in controlling seizures in Wolf-Hirschhorn syndrome patients.

Show evidence (2 references)

PMID:37075791 SUPPORT

"The most effective ASM was levetiracetam. Although WHS-associated epilepsy is intractable with frequent SE occurrence during infancy, improvement in seizure control is expected with age. Levetiracetam may be a novel ASM for WHS."

This study found levetiracetam to be the most effective antiseizure medication for Wolf-Hirschhorn syndrome.

PMID:41303083 PARTIAL

"Valproic acid and levetiracetam were the most commonly used treatments."

This cohort study confirms that levetiracetam is one of the most commonly used antiseizure medications for WHS.

Seizure Management with Valproic Acid

Action: Pharmacotherapy NCIT:C15986

Agent: valproic acid ↗

Valproic acid is commonly used for epilepsy management in Wolf-Hirschhorn syndrome.

Show evidence (1 reference)

PMID:41303083 SUPPORT

"Valproic acid and levetiracetam were the most commonly used treatments."

This large cohort study indicates valproic acid is one of the most frequently prescribed antiseizure medications for WHS.

Growth Hormone Therapy

Action: Pharmacotherapy NCIT:C15986

Recombinant human growth hormone therapy for patients with concurrent growth hormone deficiency.

Show evidence (1 reference)

PMID:41017003 PARTIAL

"Across 11 years of rhGH, height improved from ~ - 4.2 to ~ - 1.3 SDS with normalized height velocity and a prolonged but uneventful pubertal course. No major adverse effects were observed. Muscle tone improvement was also noted with treatment initiation."

This case report demonstrates long-term efficacy and safety of recombinant human growth hormone therapy in WHS patients with growth hormone deficiency.

Early Aggressive Seizure Management

Action: Pharmacotherapy NCIT:C15986

Early aggressive management using multiple antiseizure medications may be critical to improve neurological prognosis.

Show evidence (1 reference)

PMID:41303083 SUPPORT

"While some patients show improvement with age, early aggressive management using appropriate ASMs may be critical to improve neurological prognosis."

This study suggests early aggressive seizure management may improve long-term neurological outcomes in WHS.

Multidisciplinary Rehabilitation Therapy

Action: physical therapy MAXO:0000011

Multidisciplinary rehabilitation including physical therapy, speech and communication therapy, sign language, and occupational therapy is the standard of care to address the developmental delay, hypotonia, and motor/communication impairments seen in WHS.

Show evidence (1 reference)

PMID:20301362 SUPPORT Human Clinical

"Treatment includes: rehabilitation, speech/communication therapy and sign language"

GeneReviews lists rehabilitation and speech/communication therapy as core management for WHS.

Feeding Support

Action: dietary intervention MAXO:0000088

Special feeding techniques, gavage feeding, and gastrostomy placement are recommended for the feeding difficulties common in WHS, which contribute to postnatal growth deficiency.

Show evidence (1 reference)

PMID:20301362 SUPPORT Human Clinical

"special feeding techniques, gavage feeding, and/or gastrostomy for feeding difficulties"

GeneReviews recommends graduated feeding support for the WHS feeding-difficulty phenotype.

Genetic Counseling

Action: genetic counseling MAXO:0000079

Genetic counseling and parental karyotyping are recommended for families of affected individuals because ~40-45% of WHS deletions arise from unbalanced parental translocations that confer recurrence risk.

Show evidence (1 reference)

PMID:20301362 SUPPORT Human Clinical

"Risks to family members depend on the mechanism of origin of the deletion. Prenatal testing is possible for families in which one parent is known to be a carrier of a chromosome rearrangement involving 4p16.3."

GeneReviews establishes the indication for genetic counseling and prenatal testing in WHS families.

{ }

Source YAML

click to show

name: Wolf-Hirschhorn_Syndrome
creation_date: '2026-01-07T21:37:01Z'
updated_date: '2026-05-02T03:30:00Z'
description: >
  Wolf-Hirschhorn syndrome (WHS) is a contiguous gene deletion disorder caused
  by hemizygous deletion of the distal short arm of chromosome 4 (4p16.3).
  Core features are a "Greek warrior helmet" facial gestalt, prenatal-onset
  growth deficiency, intellectual disability, hypotonia, and seizures (in
  90-100% of children). The phenotype reflects haploinsufficiency of multiple
  genes within the deleted segment, including the histone H3K36
  methyltransferase NSD2/WHSC1 (a master regulator of developmental
  transcription that interacts with Nkx2-5 and other tissue-specific
  transcription factors), the mitochondrial K+/H+ and Ca2+ exchanger LETM1,
  the synaptic and neurodevelopmental genes CPLX1, CTBP1 and PIGG, the
  craniofacial/skeletal regulator MSX1, and the FGF receptor FGFR3. WHS is
  thus best modeled as a synergistic, multi-gene contiguous deletion
  disorder rather than a single-gene Mendelian condition.
disease_term:
  preferred_term: Wolf-Hirschhorn syndrome
  term:
    id: MONDO:0008684
    label: Wolf-Hirschhorn syndrome
category: Genetic
parents:
- Chromosomal Disorder
synonyms:
- 4p- syndrome
- 4p deletion syndrome
- Pitt-Rogers-Danks syndrome
- chromosome 4p16.3 deletion syndrome
- distal deletion 4p
- distal monosomy 4p
prevalence:
- population: Global
  percentage: 0.002-0.005
  evidence:
  - reference: PMID:32914558
    reference_title: "Wolf-Hirschhorn syndrome: A case series from India."
    supports: SUPPORT
    snippet: "Wolf-Hirschhorn syndrome (WHS) (OMIM#194190) is a contiguous gene syndrome with estimated prevalence being around 1 in 50,000 births."
    explanation: This provides the birth prevalence estimate which translates to approximately 0.002% of the population.
  - reference: PMID:34572183
    reference_title: "Wolf-Hirschhorn Syndrome: Clinical and Genetic Study of 7 New Cases, and Mini Review."
    supports: PARTIAL
    snippet: "Wolf-Hirschhorn syndrome (WHS), a rare disorder determined by distal 4p deletion, is characterized by a pre and postnatal growth retardation, hypotonia, intellectual disability, epilepsy, craniofacial dysmorphism, and congenital fusion anomalies."
    explanation: This confirms Wolf-Hirschhorn syndrome is a rare disorder with characteristic features.
progression:
- phase: Onset
  age_range: Antenatal-Neonatal
  evidence:
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: SUPPORT
    snippet: "Wolf-Hirschhorn syndrome is a rare genetic syndrome caused by a heterozygous deletion on chromosome 4p16.3 and is characterized by a \"Greek warrior helmet\" facies, hypotonia, developmental delay, seizures, structural central nervous system defects, intrauterine growth restriction, sketelal anomalies, cardiac defects, abnormal tooth development, and hearing loss."
    explanation: This identifies intrauterine growth restriction, indicating antenatal onset of the syndrome.
pathophysiology:
- name: 4p16.3 Contiguous Gene Deletion
  description: >
    Wolf-Hirschhorn syndrome is a contiguous gene deletion disorder caused
    by hemizygous loss of distal chromosome 4 (4p16.3). Two adjacent
    "critical regions" lie ~1.8-2.0 Mb from the 4p telomere: WHSCR (a
    ~165 kb interval encompassing parts of WHSC1/NSD2 and WHSC2/NELFA)
    and WHSCR-2 (a ~300-600 kb interval that includes the 5' end of
    WHSC1/NSD2 and all of LETM1). A separate ~197 kb terminal seizure
    susceptibility region (containing PIGG, ZNF721 and ABCA11P) lies
    ~368 kb from the 4p telomere. Phenotypic severity scales broadly
    with deletion size, but individual features track more tightly with
    which dosage-sensitive genes are removed.
  evidence:
  - reference: PMID:32914558
    reference_title: "Wolf-Hirschhorn syndrome: A case series from India."
    supports: SUPPORT
    snippet: "The syndrome is caused by deletion of a critical region (Wolf-Hirschhorn Syndrome Critical region-WHSCR) on chromosome 4p16.3."
    explanation: This establishes the genetic basis of Wolf-Hirschhorn syndrome as a deletion of the critical region on 4p16.3.
  - reference: PMID:26747863
    reference_title: "Chromosomal microarray testing identifies a 4p terminal region associated with seizures in Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Wolf-Hirschhorn syndrome (WHS) is a contiguous gene deletion syndrome involving variable size deletions of the 4p16.3 region."
    explanation: Establishes WHS as a contiguous gene deletion syndrome of variable size.
  - reference: PMID:26747863
    reference_title: "Chromosomal microarray testing identifies a 4p terminal region associated with seizures in Wolf-Hirschhorn syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Two adjacent regions, located approximately 1.8–2.0 Mbp from the 4p terminus, are each proposed to be the minimal region of deletion necessary to observe the core WHS features."
    explanation: Defines WHSCR/WHSCR-2 as the historically recognized critical regions for the core WHS phenotype.
  - reference: PMID:18474167
    reference_title: "Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    snippet: "We report a case of a rare chromosomal disorder, Wolf-Hirschhorn syndrome, caused by deletion of short arm of chromosome 4."
    explanation: This confirms that Wolf-Hirschhorn syndrome results from deletion of the short arm of chromosome 4.
  downstream:
  - target: NSD2 (WHSC1) Haploinsufficiency
    description: Loss of one copy of NSD2/WHSC1 within WHSCR/WHSCR-2 reduces H3K36 dimethyltransferase dosage.
    causal_link_type: DIRECT
  - target: LETM1 Haploinsufficiency and Mitochondrial Ion Dyshomeostasis
    description: Loss of LETM1, located in WHSCR-2, halves the mitochondrial K+/H+ and Ca2+/H+ exchanger.
    causal_link_type: DIRECT
  - target: Telomeric 4p Seizure-Susceptibility Region Haploinsufficiency
    description: Most WHS deletions extend to the 4p terminus, removing the ~197 kb terminal region containing PIGG and ZNF721.
    causal_link_type: DIRECT
  - target: MSX1 Haploinsufficiency
    description: Larger 4p deletions remove MSX1, a craniofacial/odontogenic transcription factor.
    causal_link_type: DIRECT
  - target: FGFR3 Haploinsufficiency
    description: FGFR3 lies just distal to the WHS critical regions and is co-deleted in most patients.
    causal_link_type: DIRECT
- name: NSD2 (WHSC1) Haploinsufficiency
  description: >
    NSD2 (also called WHSC1 or MMSET) encodes a SET-domain histone
    methyltransferase that dimethylates lysine 36 of histone H3
    (H3K36me2). NSD2 partners with cell-type-specific transcription
    factors (e.g., Sall1/Sall4/Nanog in embryonic stem cells, Nkx2-5 in
    embryonic heart) to deposit H3K36 marks at developmental gene loci,
    preventing inappropriate transcription. Hemizygous loss of NSD2 is
    present in essentially all WHS deletions and is considered a major
    driver of the craniofacial, growth, neurodevelopmental and
    cardiovascular phenotypes.
  gene:
    preferred_term: NSD2
    term:
      id: hgnc:12766
      label: NSD2
  biological_processes:
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: DECREASED
  - preferred_term: regulation of transcription by RNA polymerase II
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
    modifier: DECREASED
  molecular_functions:
  - preferred_term: histone methyltransferase activity
    term:
      id: GO:0042054
      label: histone methyltransferase activity
    modifier: DECREASED
  - preferred_term: histone H3K36 dimethyltransferase activity
    term:
      id: GO:0140954
      label: histone H3K36 dimethyltransferase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:25942451
    reference_title: "The NSD family of protein methyltransferases in human cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NSD2 haploinsufficiency causes Wolf-Hirschhorn syndrome"
    explanation: Cancer-biology review that asserts NSD2 haploinsufficiency as the molecular cause of WHS.
  - reference: PMID:26092122
    reference_title: "Auditory hair cell defects as potential cause for sensorineural deafness in Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "WHSC1 is a histone methyltransferase (HMT) that catalyses the addition of methyl groups to lysine 36 on histone 3. In humans, WHSC1 haploinsufficiency is associated with all known cases of Wolf-Hirschhorn syndrome (WHS)."
    explanation: Names WHSC1/NSD2 as the histone methyltransferase whose haploinsufficiency underlies WHS.
  - reference: PMID:19483677
    reference_title: "A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the H3K36me3-specific histone methyltransferase (HMTase) Wolf-Hirschhorn syndrome candidate 1 (WHSC1, also known as NSD2 or MMSET) functions in transcriptional regulation together with developmental transcription factors whose defects overlap with the human disease Wolf-Hirschhorn syndrome (WHS)"
    explanation: Identifies WHSC1/NSD2 as the H3K36 methyltransferase that partners with developmental transcription factors implicated in WHS.
  downstream:
  - target: Impaired H3K36 Dimethylation and Developmental Gene Mis-regulation
    description: Reduced NSD2 dosage halves H3K36me2 deposition at developmental gene loci normally co-bound by tissue-specific transcription factors.
    causal_link_type: DIRECT
  - target: Cranial Neural Crest Cell Migration Defect
    description: WHSC1/NSD2 is expressed in jaw, face and CNS tissues that depend on cranial neural crest, and its dysregulation has been linked to defective neural crest migration.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Loss of H3K36me2/me3 marks at neural crest target genes
    - Wnt and Twist signaling dysregulation
- name: Impaired H3K36 Dimethylation and Developmental Gene Mis-regulation
  description: >
    NSD2 normally deposits H3K36me2 at intergenic and gene-body chromatin
    of euchromatic developmental gene loci. Loss of one functional NSD2
    allele reduces global H3K36me2 and impairs co-recruitment of DNMT3A
    and other readers, blunting transcription of developmental targets
    that NSD2 co-regulates with cell-type-specific transcription factors
    such as Nkx2-5 in the embryonic heart. In Whsc1-deficient mice, this
    leads to growth retardation and a constellation of WHS-like midline
    defects, including congenital cardiovascular anomalies, that are
    aggravated by Nkx2-5 heterozygosity. Zebrafish DrWhsc1 morphants
    similarly fail to dimethylate H3K36 and develop endbrain
    enlargement, abnormal cartilage, reduced bone and incomplete motor
    neuron formation.
  biological_processes:
  - preferred_term: regulation of transcription by RNA polymerase II
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
    modifier: DYSREGULATED
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: DECREASED
  molecular_functions:
  - preferred_term: histone H3K36 dimethyltransferase activity
    term:
      id: GO:0140954
      label: histone H3K36 dimethyltransferase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:19483677
    reference_title: "A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Whsc1-deficient mice showed growth retardation and various WHS-like midline defects, including congenital cardiovascular anomalies."
    explanation: Mouse Whsc1 deficiency recapitulates growth retardation and midline/cardiac defects of WHS.
  - reference: PMID:19483677
    reference_title: "A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The effects of Whsc1 haploinsufficiency were increased in Nkx2-5 heterozygous mutant hearts, indicating their functional link."
    explanation: Establishes the NSD2/WHSC1-Nkx2-5 transcriptional axis as a driver of WHS cardiac phenotypes.
  - reference: PMID:20946879
    reference_title: "Functional characterization of the zebrafish WHSC1-related gene, a homolog of human NSD2."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Morpholino oligonucleotides for the DrWhsc1 gene affected early embryogenesis in zebrafish, such as endbrain enlargement, abnormal cartilage, marked reduction of bone, and incomplete motor neuron formation."
    explanation: Zebrafish Whsc1 knockdown produces brain, skeletal and motor neuron phenotypes that mirror WHS features.
  - reference: PMID:20946879
    reference_title: "Functional characterization of the zebrafish WHSC1-related gene, a homolog of human NSD2."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "suppression of the DrWhsc1 gene or defect in the SET domain of DrWhsc1 resulted in impairment of di-methylation of histone H3K36 at early embryogenesis"
    explanation: Establishes WHSC1/NSD2 SET domain as required for embryonic H3K36 dimethylation.
  downstream:
  - target: Severe Delayed Psychomotor Development
    description: Loss of H3K36me2 at neurodevelopmental target genes contributes to brain developmental delay.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Intellectual Disability
    description: Mis-regulation of neuronal differentiation/transcription programs contributes to cognitive impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Intrauterine Growth Retardation
    description: Whsc1-deficient mice show growth retardation phenocopying prenatal growth deficiency in WHS.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Postnatal Growth Retardation
    description: Persistent NSD2-dependent transcriptional defects underlie ongoing growth failure after birth.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Congenital Heart Defects
    description: Failure to deposit H3K36me at Nkx2-5 cardiac targets disrupts outflow tract and septal development.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Skeletal Anomalies
    description: Reduced H3K36me2 at osteochondral developmental loci impairs cartilage and bone formation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: LETM1 Haploinsufficiency and Mitochondrial Ion Dyshomeostasis
  description: >
    LETM1 lies in WHSCR-2 and encodes an inner-mitochondrial-membrane
    protein that catalyses K+/H+ exchange and Ca2+/H+ antiport, and
    controls mitochondrial volume, membrane potential and OXPHOS protein
    integrity. Hemizygous loss in WHS halves LETM1 dosage, producing
    impaired mitochondrial K+ efflux, perturbed Ca2+ handling, lower
    brain ATP and increased seizure susceptibility in mouse models.
    LETM1 has long been treated as the major candidate gene for
    WHS-associated seizures, although patients with deletions sparing
    LETM1 can still have seizures, indicating that LETM1
    haploinsufficiency is necessary but not sufficient.
  gene:
    preferred_term: LETM1
    term:
      id: hgnc:6556
      label: LETM1
  cellular_components:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  biological_processes:
  - preferred_term: mitochondrial calcium ion homeostasis
    term:
      id: GO:0051560
      label: mitochondrial calcium ion homeostasis
    modifier: DECREASED
  - preferred_term: potassium ion homeostasis
    term:
      id: GO:0055075
      label: potassium ion homeostasis
    modifier: DECREASED
  evidence:
  - reference: PMID:24738919
    reference_title: "Unusual 4p16.3 deletions suggest an additional chromosome region for the Wolf-Hirschhorn syndrome-associated seizures disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LETM1, encoding a mitochondrial protein playing a role in K(+) /H(+) exchange and in Ca(2+) homeostasis, is currently considered the major candidate gene."
    explanation: Establishes LETM1 as the historically major candidate gene for WHS seizures and its mitochondrial K+/H+ and Ca2+ functions.
  - reference: PMID:36055214
    reference_title: "Bi-allelic LETM1 variants perturb mitochondrial ion homeostasis leading to a clinical spectrum with predominant nervous system involvement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Leucine zipper-EF-hand containing transmembrane protein 1 (LETM1) encodes an inner mitochondrial membrane protein with an osmoregulatory function controlling mitochondrial volume and ion homeostasis."
    explanation: Defines LETM1's molecular function as the inner-mitochondrial-membrane osmoregulator.
  - reference: PMID:36055214
    reference_title: "Bi-allelic LETM1 variants perturb mitochondrial ion homeostasis leading to a clinical spectrum with predominant nervous system involvement."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "bi-allelic LETM1 variants are associated with defective mitochondrial K+ efflux, swollen mitochondrial matrix structures, and loss of important mitochondrial oxidative phosphorylation protein components"
    explanation: Bi-allelic loss-of-function LETM1 variants confirm the cellular consequences of LETM1 loss that are partially recapitulated in WHS heterozygotes.
  - reference: PMID:23963300
    reference_title: "Deletions involving genes WHSC1 and LETM1 may be necessary, but are not sufficient to cause Wolf-Hirschhorn Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Within this region, haploinsufficiency of the genes WHSC1 and LETM1 is thought to be a major contributor to the pathogenesis of WHS."
    explanation: Genotype-phenotype analysis supports WHSC1/LETM1 haploinsufficiency as a major (but not exclusive) WHS driver.
  downstream:
  - target: Seizures
    description: Mitochondrial K+/H+ and Ca2+ dyshomeostasis with reduced brain ATP lowers neuronal seizure threshold.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced brain ATP and impaired oxidative phosphorylation
    - Mitochondrial Ca2+ overload and ROS production
  - target: Hypotonia
    description: Mitochondrial bioenergetic deficit affects skeletal-muscle and neuromuscular tone.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Telomeric 4p Seizure-Susceptibility Region Haploinsufficiency
  description: >
    High-resolution chromosomal microarray mapping (n=48) refined an
    independent seizure-susceptibility region to a ~197 kb interval
    starting ~368 kb from the 4p telomere, distal to LETM1 and
    containing PIGG, ZNF721 and the pseudogene ABCA11P. Patients with
    interstitial deletions whose distal breakpoint preserves the
    terminal 751 kb (and thus this region) lack seizures, while all
    patients whose deletions include this region have seizures, even
    when LETM1 is deleted. Network analysis of WHS seizure cohorts
    shows that PIGG, CPLX1, CTBP1 and LETM1 act through partially
    overlapping mechanisms converging on impaired neuronal
    communication, supporting a synergistic-haploinsufficiency model.
  genes:
  - preferred_term: PIGG
    term:
      id: hgnc:25985
      label: PIGG
  - preferred_term: CPLX1
    term:
      id: hgnc:2309
      label: CPLX1
  - preferred_term: CTBP1
    term:
      id: hgnc:2494
      label: CTBP1
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: DECREASED
  - preferred_term: synaptic vesicle exocytosis
    term:
      id: GO:0016079
      label: synaptic vesicle exocytosis
    modifier: DECREASED
  - preferred_term: trans-synaptic signaling
    term:
      id: GO:0099537
      label: trans-synaptic signaling
    modifier: DECREASED
  evidence:
  - reference: PMID:26747863
    reference_title: "Chromosomal microarray testing identifies a 4p terminal region associated with seizures in Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identify a small terminal region of chromosome 4p that represents a seizure susceptibility region. Deletion of this region in the context of WHS is sufficient for seizure occurrence."
    explanation: Defines the terminal 4p seizure-susceptibility region whose deletion is sufficient for WHS-associated seizures.
  - reference: PMID:26747863
    reference_title: "Chromosomal microarray testing identifies a 4p terminal region associated with seizures in Wolf-Hirschhorn syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Some of these deletions suggest that LETM1 deletion is neither necessary nor sufficient for the expression of a seizure phenotype in individuals with WHS"
    explanation: Refutes a single-gene LETM1 model and motivates the search for additional seizure-susceptibility genes.
  - reference: PMID:24738919
    reference_title: "Unusual 4p16.3 deletions suggest an additional chromosome region for the Wolf-Hirschhorn syndrome-associated seizures disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "haploinsufficiency not limited to LETM1 but including other genes acts as a risk factor for the WHS-associated seizure disorder, according to a comorbidity model of pathogenesis"
    explanation: Supports a comorbidity/synergistic model of WHS seizures involving LETM1 and additional genes.
  - reference: PMID:35278209
    reference_title: "Distinct Epileptogenic Mechanisms Associated with Seizures in Wolf-Hirschhorn Syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "The proximity among the previous reported haploinsufficient candidate genes (PIGG, CPLX1, CTBP1, LETM1) and disease genes associated with epilepsy suggests not just one, but different impaired mechanisms in cellular networks responsible for the balance of neuronal activity in WHS patients, from which neuron communication is the most impaired in WHS-related seizures."
    explanation: Network analysis identifies PIGG, CPLX1, CTBP1 and LETM1 as a synergistic seizure-susceptibility module converging on neuronal communication.
  downstream:
  - target: Seizures
    description: Synergistic haploinsufficiency of PIGG, CPLX1, CTBP1 and LETM1 disrupts neuronal communication and lowers seizure threshold.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Defective GPI-anchor maturation (PIGG)
    - Impaired SNARE-mediated synaptic vesicle release (CPLX1)
    - Disrupted CtBP1-mediated transcriptional repression in neurons
- name: Cranial Neural Crest Cell Migration Defect
  description: >
    Most of the WHS-affected midline structures (Greek-warrior-helmet
    facies, palatal clefts, cardiac outflow tract, mandibular and
    auricular cartilage, dental papilla) derive from cranial neural
    crest cells. Multiple WHS-region genes (NSD2/WHSC1, LETM1, TACC3,
    FGFR3) are enriched in migratory neural crest, and their combined
    haploinsufficiency is proposed to perturb neural crest cell motility,
    epithelial-to-mesenchymal transition (via NSD2-Twist regulation) and
    chemotactic responses to FGF8 (via FGFR1/3). The result is reduced
    delivery and patterning of neural crest derivatives at the face,
    ear, jaw and conotruncal heart.
  cell_types:
  - preferred_term: migratory neural crest cell
    term:
      id: CL:0000333
      label: migratory neural crest cell
  - preferred_term: migratory cardiac neural crest cell
    term:
      id: CL:2000073
      label: migratory cardiac neural crest cell
  locations:
  - preferred_term: cranial neural crest
    term:
      id: UBERON:0003099
      label: cranial neural crest
  - preferred_term: embryonic head
    term:
      id: UBERON:0008816
      label: embryonic head
  biological_processes:
  - preferred_term: neural crest cell migration
    term:
      id: GO:0001755
      label: neural crest cell migration
    modifier: DECREASED
  evidence:
  - reference: PMID:27777068
    reference_title: "Exploring the developmental mechanisms underlying Wolf-Hirschhorn Syndrome: Evidence for defects in neural crest cell migration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "we propose a novel characterization for WHS as a pathophysiology owing in part to defects in neural crest cell motility and migration during development."
    explanation: Review proposes defective cranial neural crest migration as a unifying mechanism for WHS midline phenotypes.
  - reference: PMID:27777068
    reference_title: "Exploring the developmental mechanisms underlying Wolf-Hirschhorn Syndrome: Evidence for defects in neural crest cell migration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the formation of structures of the face and jaw, as well as certain glial cell populations in the brain, depend on neural crest cell migration"
    explanation: Establishes the developmental dependence of WHS-affected craniofacial structures on cranial neural crest migration.
  downstream:
  - target: Characteristic Facial Features
    description: Defective migration of cranial neural crest into the frontonasal and maxillary processes shapes the Greek-warrior-helmet facies.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Hypertelorism
    description: Aberrant cranial-neural-crest patterning of midfacial structures contributes to widely spaced eyes.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cleft Lip or Palate
    description: Disrupted neural crest delivery to the palatal shelves contributes to midline cleft.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Congenital Heart Defects
    description: Reduced cardiac neural crest migration into the outflow tract contributes to septal and conotruncal defects.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: FGFR3 Haploinsufficiency
  description: >
    FGFR3 lies just distal to the WHSC1/LETM1 critical regions in 4p16.3
    and is co-deleted in most WHS patients. FGFR3 normally inhibits
    chondrocyte proliferation and supports inner-ear cochlear hair cell
    development; together with FGFR1, FGFR3 also mediates cardiac
    neural-crest chemotaxis to FGF8. Loss of one copy contributes to
    skeletal anomalies and to inner-ear and conductive hearing
    abnormalities. Whsc1-deficient mice show cochlear hair-cell
    stereocilia defects that recapitulate WHS sensorineural hearing
    loss, identifying NSD2 as a complementary contributor at the
    cochlear level.
  gene:
    preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  - preferred_term: auditory hair cell
    term:
      id: CL:0000202
      label: auditory hair cell
  locations:
  - preferred_term: internal ear
    term:
      id: UBERON:0001846
      label: internal ear
  - preferred_term: skeletal system
    term:
      id: UBERON:0001434
      label: skeletal system
  biological_processes:
  - preferred_term: fibroblast growth factor receptor signaling pathway
    term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:26092122
    reference_title: "Auditory hair cell defects as potential cause for sensorineural deafness in Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "WHSC1-deficient mice display craniofacial defects that overlap with WHS, including cochlea anomalies. Although auditory hair cells are specified normally, their stereocilia hair bundles required for sound perception fail to develop the appropriate morphology."
    explanation: Whsc1-deficient mice phenocopy WHS sensorineural hearing loss via cochlear hair-bundle defects.
  - reference: PMID:27777068
    reference_title: "Exploring the developmental mechanisms underlying Wolf-Hirschhorn Syndrome: Evidence for defects in neural crest cell migration."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "FGFRs 1 and 3 have recently been implicated in the chemotactic response of cardiac neural crest cells to FGF8 in the pharyngeal ecto-and endoderm in chick embryos, operating upstream of the MAPK/ERK pathway"
    explanation: Provides mechanism by which FGFR3 haploinsufficiency may compromise cardiac neural-crest chemotaxis.
  downstream:
  - target: Skeletal Anomalies
    description: Reduced FGFR3 signaling alters chondrocyte regulation and skeletal patterning.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Sensorineural Hearing Loss
    description: Defective cochlear hair-bundle maturation impairs sound transduction.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: MSX1 Haploinsufficiency
  description: >
    Larger 4p deletions extend proximally to encompass MSX1, a homeobox
    transcription factor essential for tooth-bud and palatal-shelf
    development. Heterozygous loss of MSX1 causes non-syndromic tooth
    agenesis and orofacial clefts on its own; in WHS its haploinsufficiency
    is proposed to contribute to hypodontia, abnormal tooth morphology
    and cleft-palate susceptibility, on top of the broader cranial
    neural-crest dysfunction.
  gene:
    preferred_term: MSX1
    term:
      id: hgnc:7391
      label: MSX1
  cell_types:
  - preferred_term: odontoblast
    term:
      id: CL:0000060
      label: odontoblast
  biological_processes:
  - preferred_term: odontogenesis
    term:
      id: GO:0042476
      label: odontogenesis
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:29628999
    reference_title: "A review on non-syndromic tooth agenesis associated with PAX9 mutations."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutation of candidate genes PAX9 and MSX1 have been identified as the main causes of hypodontia and oligodontia"
    explanation: Identifies MSX1 as a primary disease gene for tooth agenesis. Evidence is extrapolated from non-syndromic tooth agenesis literature; no WHS-specific MSX1 publication is cited here.
  downstream:
  - target: Tooth Abnormalities
    description: MSX1 haploinsufficiency disrupts tooth-bud induction, contributing to hypodontia and abnormal dental morphology in WHS.
    causal_link_type: DIRECT
  - target: Cleft Lip or Palate
    description: MSX1 dosage is required for palatal-shelf fusion; its loss contributes to cleft palate risk in larger 4p deletions.
    causal_link_type: DIRECT
- name: NSD2-Dependent B-cell Maturation Defect
  description: >
    Beyond its roles in development, NSD2/WHSC1 is required in B
    lymphocytes for class-switch recombination and B1-cell development.
    NSD2 haploinsufficiency in WHS therefore plausibly contributes to the
    humoral immunodeficiency (low IgM/IgG3/IgA, hypogammaglobulinemia)
    that has been documented in a subset of WHS patients and that
    underpins their susceptibility to recurrent infections.
  gene:
    preferred_term: NSD2
    term:
      id: hgnc:12766
      label: NSD2
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  molecular_functions:
  - preferred_term: histone H3K36 dimethyltransferase activity
    term:
      id: GO:0140954
      label: histone H3K36 dimethyltransferase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:32862441
    reference_title: "NSD2 controls the development of B1 cells and humoral immunity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "NSD2 is required for B cell class switch recombination"
    explanation: NSD2 is required for normal B-cell class switching, providing a mechanism for WHS-associated humoral immunodeficiency.
  - reference: PMID:32862441
    reference_title: "NSD2 controls the development of B1 cells and humoral immunity."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "deletion of the catalytic domain of NSD2 in primary B cells impairs the generation of B1 lineage. Thus, NSD2, a histone H3 K36 dimethylase, is the first-in-class epigenetic regulator of a B-cell lineage in mice."
    explanation: NSD2 SET-domain loss in mouse B cells impairs B1 cell development.
  downstream:
  - target: Immunodeficiency
    description: NSD2-dependent B-cell class switching and B1 lineage defects can contribute to humoral immune impairment in WHS.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
phenotypes:
- category: Craniofacial
  name: Characteristic Facial Features
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: The distinctive facies includes broad nasal bridge continuing to the forehead (Greek warrior helmet appearance), microcephaly, high forehead with prominent glabella, hypertelorism, and micrognathia.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:25137600
    reference_title: "Wolf-Hirschhorn syndrome: a case study and disease overview."
    supports: SUPPORT
    snippet: "The major features of this disorder include a characteristic facial appearance known as the \"Greek helmet,\" delayed growth and development; prenatally and postnatally, intellectual disabilities, and seizures."
    explanation: This establishes the characteristic Greek helmet facial appearance as a major diagnostic feature.
  - reference: PMID:32914558
    reference_title: "Wolf-Hirschhorn syndrome: A case series from India."
    supports: SUPPORT
    snippet: "Its core features are typical facial gestalt, growth retardation, intellectual disability, or developmental delay and seizures."
    explanation: This identifies the typical facial gestalt as one of the core features of Wolf-Hirschhorn syndrome.
- category: Craniofacial
  name: Microcephaly
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Small head circumference is a consistent feature of Wolf-Hirschhorn syndrome.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:18474167
    reference_title: "Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    snippet: "It was characterized by well-described facial appearance, seizures, microcephaly and midline closure defects along with growth and mental retardation."
    explanation: This establishes microcephaly as a characteristic feature of Wolf-Hirschhorn syndrome.
- category: Craniofacial
  name: Hypertelorism
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Widely spaced eyes are a characteristic feature contributing to the distinctive facial appearance.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:9774859
    reference_title: "Wolf-Hirschhorn syndrome: case report and review of the chromosomal aberrations associated with diaphragmatic defects."
    supports: SUPPORT
    snippet: "At the autopsy, the propositus showed microcephaly, prominent glabella, broad bridge of the nose, ocular hypertelorism, poorly differentiated and low-set ears, bilateral palatoschisis, and micrognathia."
    explanation: This case report confirms ocular hypertelorism as a characteristic craniofacial feature of Wolf-Hirschhorn syndrome.
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: SUPPORT
    snippet: "Ocular findings included normal intraocular pressures and corneal diameters, large-angle exotropia, downward slanting of the palpebral fissures, absent eyelid creases, upper and lower eyelid retraction with shortage of the anterior eyelid lamellae, euryblepharon, lagophthalmos with poor Bell's reflex and exposure keratopathy, hypertelorism, Axenfeld's anomaly, megalopapillae, and cavitary optic disc anomaly."
    explanation: This documents hypertelorism as one of the ocular findings in Wolf-Hirschhorn syndrome.
- category: Growth
  name: Intrauterine Growth Retardation
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Marked intrauterine growth retardation is a consistent prenatal finding in Wolf-Hirschhorn syndrome.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: PMID:25137600
    reference_title: "Wolf-Hirschhorn syndrome: a case study and disease overview."
    supports: SUPPORT
    snippet: "The major features of this disorder include a characteristic facial appearance known as the \"Greek helmet,\" delayed growth and development; prenatally and postnatally, intellectual disabilities, and seizures."
    explanation: This describes delayed growth and development both prenatally and postnatally as major features.
- category: Growth
  name: Postnatal Growth Retardation
  frequency: VERY_FREQUENT
  notes: Slow postnatal weight gain and continued growth impairment are characteristic.
  phenotype_term:
    preferred_term: Postnatal growth retardation
    term:
      id: HP:0008897
      label: Postnatal growth retardation
  evidence:
  - reference: PMID:30289612
    reference_title: "Risk of hepatic neoplasms in Wolf-Hirschhorn syndrome (4p-): Four new cases and review of the literature."
    supports: SUPPORT
    snippet: "Wolf-Hirschhorn syndrome (WHS) is a rare contiguous gene deletion disorder characterized by distinctive craniofacial features, prenatal/postnatal growth deficiency, intellectual disability, and seizures."
    explanation: This establishes prenatal/postnatal growth deficiency as a characteristic feature of Wolf-Hirschhorn syndrome.
- category: Neurologic
  name: Intellectual Disability
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Intellectual disability is moderate to severe in most cases, rarely mild.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:32914558
    reference_title: "Wolf-Hirschhorn syndrome: A case series from India."
    supports: SUPPORT
    snippet: "Its core features are typical facial gestalt, growth retardation, intellectual disability, or developmental delay and seizures."
    explanation: This identifies intellectual disability as one of the core features of Wolf-Hirschhorn syndrome.
  - reference: PMID:25137600
    reference_title: "Wolf-Hirschhorn syndrome: a case study and disease overview."
    supports: SUPPORT
    snippet: "The major features of this disorder include a characteristic facial appearance known as the \"Greek helmet,\" delayed growth and development; prenatally and postnatally, intellectual disabilities, and seizures."
    explanation: This establishes intellectual disabilities as a major feature of the disorder.
  - reference: PMID:18474167
    reference_title: "Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    snippet: "It was characterized by well-described facial appearance, seizures, microcephaly and midline closure defects along with growth and mental retardation."
    explanation: This confirms mental retardation (intellectual disability) as a characteristic feature.
- category: Neurologic
  name: Severe Delayed Psychomotor Development
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Severe developmental delays affecting motor skills, speech, and adaptive functioning.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: SUPPORT
    snippet: "Wolf-Hirschhorn syndrome is a rare genetic syndrome caused by a heterozygous deletion on chromosome 4p16.3 and is characterized by a \"Greek warrior helmet\" facies, hypotonia, developmental delay, seizures, structural central nervous system defects, intrauterine growth restriction, sketelal anomalies, cardiac defects, abnormal tooth development, and hearing loss."
    explanation: This identifies developmental delay as one of the characteristic features of Wolf-Hirschhorn syndrome.
  - reference: PMID:40404199
    reference_title: "Clinical features, behaviour and language in Wolf-Hirschhorn syndrome."
    supports: PARTIAL
    snippet: "Wolf-Hirschhorn syndrome (WHS) is associated with intellectual disability and multiple congenital anomalies."
    explanation: This confirms the association of Wolf-Hirschhorn syndrome with intellectual disability and developmental impairment.
- category: Neurologic
  name: Seizures
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Seizures are a very frequent feature, occurring in the majority of patients with Wolf-Hirschhorn syndrome.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:32914558
    reference_title: "Wolf-Hirschhorn syndrome: A case series from India."
    supports: SUPPORT
    snippet: "Its core features are typical facial gestalt, growth retardation, intellectual disability, or developmental delay and seizures."
    explanation: This identifies seizures as one of the core features of Wolf-Hirschhorn syndrome.
  - reference: PMID:25137600
    reference_title: "Wolf-Hirschhorn syndrome: a case study and disease overview."
    supports: SUPPORT
    snippet: "The major features of this disorder include a characteristic facial appearance known as the \"Greek helmet,\" delayed growth and development; prenatally and postnatally, intellectual disabilities, and seizures."
    explanation: This establishes seizures as a major feature of the disorder.
  - reference: PMID:18474167
    reference_title: "Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    snippet: "It was characterized by well-described facial appearance, seizures, microcephaly and midline closure defects along with growth and mental retardation."
    explanation: This confirms seizures as a characteristic feature of Wolf-Hirschhorn syndrome.
- category: Neurologic
  name: Status Epilepticus
  frequency: FREQUENT
  notes: >
    Status epilepticus is a frequent and clinically significant
    complication of WHS-associated epilepsy, occurring in roughly 58%
    of patients in pediatric cohorts and contributing to neurological
    morbidity.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: PMID:41303083
    reference_title: "Epilepsy in Wolf-Hirschhorn Syndrome: Clinical Insights from a Pediatric Cohort and a Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Status epilepticus occurred in 58% of cases, with a high proportion requiring multiple ASMs."
    explanation: Pediatric WHS cohort directly quantifies status epilepticus prevalence at 58%.
- category: Neurologic
  name: Hypotonia
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Hypotonia with muscle underdevelopment is a characteristic feature.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: SUPPORT
    snippet: "Wolf-Hirschhorn syndrome is a rare genetic syndrome caused by a heterozygous deletion on chromosome 4p16.3 and is characterized by a \"Greek warrior helmet\" facies, hypotonia, developmental delay, seizures, structural central nervous system defects, intrauterine growth restriction, sketelal anomalies, cardiac defects, abnormal tooth development, and hearing loss."
    explanation: This establishes hypotonia as one of the characteristic features of Wolf-Hirschhorn syndrome.
- category: Neurologic
  name: Corpus Callosum Abnormalities
  frequency: OCCASIONAL
  notes: Structural central nervous system defects including corpus callosum abnormalities may occur.
  phenotype_term:
    preferred_term: Abnormal corpus callosum morphology
    term:
      id: HP:0001273
      label: Abnormal corpus callosum morphology
  evidence:
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: SUPPORT
    snippet: "Systemic findings included \"Greek warrior helmet\" facies, hypotonia, cleft palate, neonatal tooth eruption, talipes equinovarus, bilateral clinodactyly, clitoromegaly, partial agenesis of the corpus callosum, bilateral renal hypoplasia, and two atrial septal defects."
    explanation: This case report documents partial agenesis of the corpus callosum as a structural CNS abnormality in Wolf-Hirschhorn syndrome.
  - reference: PMID:34572183
    reference_title: "Wolf-Hirschhorn Syndrome: Clinical and Genetic Study of 7 New Cases, and Mini Review."
    supports: PARTIAL
    snippet: "In some cases, we observed seizures, structural brain abnormalities, immunodeficiencies, and renal anomalies."
    explanation: This study identifies structural brain abnormalities as a manifestation in some cases of Wolf-Hirschhorn syndrome.
- category: Cardiac
  name: Congenital Heart Defects
  frequency: FREQUENT
  notes: Congenital heart defects occur in a substantial proportion of patients.
  phenotype_term:
    preferred_term: Congenital heart defect
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: SUPPORT
    snippet: "Wolf-Hirschhorn syndrome is a rare genetic syndrome caused by a heterozygous deletion on chromosome 4p16.3 and is characterized by a \"Greek warrior helmet\" facies, hypotonia, developmental delay, seizures, structural central nervous system defects, intrauterine growth restriction, sketelal anomalies, cardiac defects, abnormal tooth development, and hearing loss."
    explanation: This identifies cardiac defects as one of the characteristic features of Wolf-Hirschhorn syndrome.
  - reference: PMID:33599186
    reference_title: "An unusual ophthalmic presentation of Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    snippet: "The infant had multiple congenital anomalies; a cleft palate, microcephalia, micrognathia, renal pelvicalyceal ectasia, atrial septal defect, transvers arcus hypoplasia, patent ductus arteriosus, hypospadias and undescended testicle."
    explanation: This case report documents specific cardiac defects (atrial septal defect, patent ductus arteriosus) in Wolf-Hirschhorn syndrome.
- category: Skeletal
  name: Skeletal Anomalies
  frequency: FREQUENT
  notes: Skeletal anomalies may include kyphosis, scoliosis, vertebral malformations, and limb abnormalities.
  phenotype_term:
    preferred_term: Abnormality of the skeletal system
    term:
      id: HP:0000924
      label: Abnormality of the skeletal system
  evidence:
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: SUPPORT
    snippet: "Wolf-Hirschhorn syndrome is a rare genetic syndrome caused by a heterozygous deletion on chromosome 4p16.3 and is characterized by a \"Greek warrior helmet\" facies, hypotonia, developmental delay, seizures, structural central nervous system defects, intrauterine growth restriction, sketelal anomalies, cardiac defects, abnormal tooth development, and hearing loss."
    explanation: This identifies skeletal anomalies as one of the characteristic features of Wolf-Hirschhorn syndrome.
  - reference: PMID:9774859
    reference_title: "Wolf-Hirschhorn syndrome: case report and review of the chromosomal aberrations associated with diaphragmatic defects."
    supports: SUPPORT
    snippet: "Midline closure defects of the cervical spine bodies, lower jaw, and skull base were seen at postmortem radiography."
    explanation: This case report documents specific skeletal abnormalities including cervical spine defects in Wolf-Hirschhorn syndrome.
- category: Genitourinary
  name: Renal Anomalies
  frequency: FREQUENT
  notes: >
    Renal/urological anomalies including renal hypoplasia and
    oligomeganephronia occur in roughly half of WHS patients,
    particularly with larger 4p deletions, and warrant routine renal
    surveillance.
  phenotype_term:
    preferred_term: Abnormality of the kidney
    term:
      id: HP:0000077
      label: Abnormality of the kidney
  evidence:
  - reference: PMID:34572183
    reference_title: "Wolf-Hirschhorn Syndrome: Clinical and Genetic Study of 7 New Cases, and Mini Review."
    supports: PARTIAL
    snippet: "In some cases, we observed seizures, structural brain abnormalities, immunodeficiencies, and renal anomalies."
    explanation: This study identifies renal anomalies as a manifestation in some cases of Wolf-Hirschhorn syndrome.
  - reference: PMID:41225980
    reference_title: "Renal Hypoplasia and Oligomeganephronia in a Fetus with Wolf-Hirschhorn Syndrome."
    supports: SUPPORT
    snippet: "It is characterized by intrauterine growth restriction (IUGR), developmental delay, epilepsy, distinctive facial features, and urinary tract anomalies, particularly renal hypoplasia."
    explanation: This identifies renal hypoplasia as a characteristic urinary tract anomaly in Wolf-Hirschhorn syndrome.
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: SUPPORT
    snippet: "Systemic findings included \"Greek warrior helmet\" facies, hypotonia, cleft palate, neonatal tooth eruption, talipes equinovarus, bilateral clinodactyly, clitoromegaly, partial agenesis of the corpus callosum, bilateral renal hypoplasia, and two atrial septal defects."
    explanation: This case report documents bilateral renal hypoplasia as a systemic finding in Wolf-Hirschhorn syndrome.
- category: Immunologic
  name: Immunodeficiency
  frequency: OCCASIONAL
  notes: Immunodeficiencies have been observed in some cases and should be looked for.
  phenotype_term:
    preferred_term: Immunodeficiency
    term:
      id: HP:0002721
      label: Immunodeficiency
  evidence:
  - reference: PMID:34572183
    reference_title: "Wolf-Hirschhorn Syndrome: Clinical and Genetic Study of 7 New Cases, and Mini Review."
    supports: SUPPORT
    snippet: "In some cases, we observed seizures, structural brain abnormalities, immunodeficiencies, and renal anomalies."
    explanation: This study identifies immunodeficiencies as a rare manifestation that should be looked for in Wolf-Hirschhorn syndrome.
- category: Craniofacial
  name: Cleft Lip or Palate
  frequency: OCCASIONAL
  notes: Cleft lip/palate may occur in some cases.
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
  evidence:
  - reference: PMID:33599186
    reference_title: "An unusual ophthalmic presentation of Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    snippet: "The infant had multiple congenital anomalies; a cleft palate, microcephalia, micrognathia, renal pelvicalyceal ectasia, atrial septal defect, transvers arcus hypoplasia, patent ductus arteriosus, hypospadias and undescended testicle."
    explanation: This case report documents cleft palate as one of the congenital anomalies in Wolf-Hirschhorn syndrome.
- category: Gastrointestinal
  name: Feeding Difficulties
  frequency: FREQUENT
  notes: >
    Feeding difficulties are highly variable but commonly recognized
    in WHS, frequently requiring special feeding techniques, gavage
    feeding or gastrostomy, and contributing to postnatal growth
    failure.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:26747863
    reference_title: "Chromosomal microarray testing identifies a 4p terminal region associated with seizures in Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "additional highly variable clinical features of WHS include, but are not limited to, feeding difficulties, congenital heart defects, hearing loss, skeletal anomalies, kidney and urinary tract malformations, and ophthalmological and dental abnormalities."
    explanation: WHS clinical-genetic literature lists feeding difficulties among the recurrent variable features.
- category: Auditory
  name: Sensorineural Hearing Loss
  frequency: OCCASIONAL
  notes: >
    Sensorineural hearing loss is reported in approximately 15% of WHS
    patients and is attributable to cochlear hair-cell defects in
    NSD2-deficient and FGFR3-deficient cochleas. (Overall hearing loss
    in WHS, predominantly conductive, occurs in >40% of patients but
    is captured separately by the Abnormality of hearing parent term.)
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:26092122
    reference_title: "Auditory hair cell defects as potential cause for sensorineural deafness in Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The cardinal feature of WHS is a craniofacial dysmorphism, which is accompanied by sensorineural hearing loss in 15% of individuals with WHS."
    explanation: Establishes sensorineural hearing loss as occurring in approximately 15% of WHS patients with a cochlear-hair-cell origin.
- category: Dental
  name: Tooth Abnormalities
  frequency: FREQUENT
  notes: >
    Dental abnormalities including hypodontia, abnormal tooth morphology,
    delayed eruption and neonatal teeth are recurrent in WHS, consistent
    with co-deletion of MSX1 in larger 4p deletions and broader cranial
    neural-crest dysfunction.
  phenotype_term:
    preferred_term: Abnormality of the dentition
    term:
      id: HP:0000164
      label: Abnormality of the dentition
  evidence:
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: SUPPORT
    snippet: "Wolf-Hirschhorn syndrome is a rare genetic syndrome caused by a heterozygous deletion on chromosome 4p16.3 and is characterized by a \"Greek warrior helmet\" facies, hypotonia, developmental delay, seizures, structural central nervous system defects, intrauterine growth restriction, sketelal anomalies, cardiac defects, abnormal tooth development, and hearing loss."
    explanation: Lists abnormal tooth development among the characteristic WHS features.
  - reference: PMID:29199884
    reference_title: "Congenital cavitary optic disc anomaly and Axenfeld's anomaly in Wolf-Hirschhorn syndrome: A case report and review of the literature."
    supports: PARTIAL
    snippet: "Systemic findings included \"Greek warrior helmet\" facies, hypotonia, cleft palate, neonatal tooth eruption, talipes equinovarus, bilateral clinodactyly, clitoromegaly, partial agenesis of the corpus callosum, bilateral renal hypoplasia, and two atrial septal defects."
    explanation: Documents neonatal tooth eruption as a specific dental abnormality observed in WHS.
genetic:
- name: Chromosome 4p16.3 Deletion
  association: Causal
  notes: >
    Most cases are sporadic de novo deletions (~55-72%); ~20-45% arise
    from unbalanced parental translocations (commonly t(4;8)), and a
    minority from ring chromosome 4 or other complex rearrangements.
    Routine karyotype detects only ~50-60% of cases; FISH targeting
    LETM1/WHSC1 reaches ~95% sensitivity and chromosomal microarray
    (CMA) is the current method of choice, providing >99% clinical
    sensitivity and detecting submicroscopic deletions <3 Mb.
  evidence:
  - reference: PMID:32914558
    reference_title: "Wolf-Hirschhorn syndrome: A case series from India."
    supports: PARTIAL
    snippet: "Less than half of the patients can be identified by conventional cytogenetics and molecular cytogenetic testing should be offered for diagnosis. Karyotyping of the parents should always be offered in a child with WHS."
    explanation: This provides important diagnostic guidance regarding the need for molecular cytogenetic testing and parental karyotyping.
  - reference: PMID:11584045
    reference_title: "An epidemiological study of Wolf-Hirschhorn syndrome: life expectancy and cause of mortality."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cases with large de novo deletions (proximal to and including p15.2) were more likely to have died than those with smaller deletions (odds ratio=5.7, 95% CI=1.7-19.9) after adjusting for age."
    explanation: Larger 4p deletions carry a 5.7-fold increased mortality, consistent with the contiguous-gene-deletion model where more haploinsufficient genes drive worse outcomes.
- name: NSD2 (WHSC1) Haploinsufficiency
  association: Causal
  gene_term:
    preferred_term: NSD2
    term:
      id: hgnc:12766
      label: NSD2
  notes: >
    NSD2/WHSC1 is the H3K36 dimethyltransferase whose hemizygous loss is
    present in essentially all classic WHS deletions. It is considered
    the major epigenetic driver of WHS craniofacial, growth, and cardiac
    phenotypes, partnering with developmental transcription factors
    such as Nkx2-5.
  evidence:
  - reference: PMID:25942451
    reference_title: "The NSD family of protein methyltransferases in human cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NSD2 haploinsufficiency causes Wolf-Hirschhorn syndrome"
    explanation: Cancer-biology review naming NSD2 haploinsufficiency as a cause of WHS.
- name: LETM1 Haploinsufficiency
  association: Contributory
  gene_term:
    preferred_term: LETM1
    term:
      id: hgnc:6556
      label: LETM1
  notes: >
    LETM1, encoding the inner-mitochondrial-membrane K+/H+ and Ca2+/H+
    exchanger, lies in WHSCR-2 and is deleted in most WHS patients. It
    has long been considered the major candidate gene for WHS-associated
    seizures, although LETM1 haploinsufficiency alone is not sufficient.
  evidence:
  - reference: PMID:24738919
    reference_title: "Unusual 4p16.3 deletions suggest an additional chromosome region for the Wolf-Hirschhorn syndrome-associated seizures disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LETM1, encoding a mitochondrial protein playing a role in K(+) /H(+) exchange and in Ca(2+) homeostasis, is currently considered the major candidate gene."
    explanation: Establishes LETM1 as the historical major candidate seizure gene.
- name: PIGG Haploinsufficiency
  association: Contributory
  gene_term:
    preferred_term: PIGG
    term:
      id: hgnc:25985
      label: PIGG
  notes: >
    PIGG lies within the refined 197 kb terminal 4p seizure-susceptibility
    region. Its haploinsufficiency, alongside CPLX1 and CTBP1, is
    implicated in the WHS-associated seizure disorder by network and
    deletion-mapping analyses.
  evidence:
  - reference: PMID:26747863
    reference_title: "Chromosomal microarray testing identifies a 4p terminal region associated with seizures in Wolf-Hirschhorn syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identify a small terminal region of chromosome 4p that represents a seizure susceptibility region. Deletion of this region in the context of WHS is sufficient for seizure occurrence."
    explanation: PIGG (within the terminal seizure-susceptibility region) contributes to the WHS seizure phenotype.
- name: CPLX1 Haploinsufficiency
  association: Contributory
  gene_term:
    preferred_term: CPLX1
    term:
      id: hgnc:2309
      label: CPLX1
  notes: >
    CPLX1 encodes Complexin-1, a SNARE-binding regulator of synaptic
    vesicle exocytosis. Its haploinsufficiency in WHS, in synergy with
    LETM1 and PIGG, contributes to the seizure phenotype.
  evidence:
  - reference: PMID:35278209
    reference_title: "Distinct Epileptogenic Mechanisms Associated with Seizures in Wolf-Hirschhorn Syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "The proximity among the previous reported haploinsufficient candidate genes (PIGG, CPLX1, CTBP1, LETM1) and disease genes associated with epilepsy suggests not just one, but different impaired mechanisms in cellular networks responsible for the balance of neuronal activity in WHS patients, from which neuron communication is the most impaired in WHS-related seizures."
    explanation: Network analysis groups CPLX1 with PIGG/CTBP1/LETM1 as a synergistic seizure-susceptibility module.
- name: CTBP1 Haploinsufficiency
  association: Contributory
  gene_term:
    preferred_term: CTBP1
    term:
      id: hgnc:2494
      label: CTBP1
  notes: >
    CTBP1 (C-terminal-binding protein 1) is a transcriptional corepressor
    expressed in brain. Its haploinsufficiency in WHS is implicated in
    seizure susceptibility and may be a pharmacologic target for future
    seizure therapy.
  evidence:
  - reference: PMID:35278209
    reference_title: "Distinct Epileptogenic Mechanisms Associated with Seizures in Wolf-Hirschhorn Syndrome."
    supports: PARTIAL
    evidence_source: COMPUTATIONAL
    snippet: "CTBP1 obtained the largest number of drug associations, reinforcing its importance for adaptations of brain circuits and its putative use as a pharmacological target for treating seizures/epilepsy in patients with WHS."
    explanation: Identifies CTBP1 as a candidate drug-targetable haploinsufficient gene in WHS.
- name: FGFR3 Haploinsufficiency
  association: Contributory
  gene_term:
    preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  notes: >
    FGFR3 lies just distal to the WHS critical regions and is co-deleted
    in most WHS patients. Its loss contributes to skeletal and cochlear
    phenotypes via altered chondrocyte and inner-ear hair-cell
    development.
  evidence:
  - reference: PMID:27777068
    reference_title: "Exploring the developmental mechanisms underlying Wolf-Hirschhorn Syndrome: Evidence for defects in neural crest cell migration."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "FGFRs 1 and 3 have recently been implicated in the chemotactic response of cardiac neural crest cells to FGF8 in the pharyngeal ecto-and endoderm in chick embryos, operating upstream of the MAPK/ERK pathway"
    explanation: FGFR3 haploinsufficiency may compromise cardiac neural-crest chemotaxis upstream of MAPK/ERK.
- name: MSX1 Haploinsufficiency
  association: Contributory
  gene_term:
    preferred_term: MSX1
    term:
      id: hgnc:7391
      label: MSX1
  notes: >
    MSX1, a homeobox transcription factor for tooth and palatal-shelf
    development, is co-deleted in larger 4p deletions and contributes
    to dental and palatal phenotypes.
  evidence:
  - reference: PMID:29628999
    reference_title: "A review on non-syndromic tooth agenesis associated with PAX9 mutations."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutation of candidate genes PAX9 and MSX1 have been identified as the main causes of hypodontia and oligodontia"
    explanation: Identifies MSX1 as a primary tooth-agenesis disease gene; mechanistic role in WHS dental phenotypes is extrapolated from this non-syndromic literature.
treatments:
- name: Seizure Management with Levetiracetam
  description: Levetiracetam has shown efficacy in controlling seizures in Wolf-Hirschhorn syndrome patients.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levetiracetam
      term:
        id: CHEBI:6437
        label: levetiracetam
  evidence:
  - reference: PMID:37075791
    reference_title: "Efficacy of Antiseizure Medications in Wolf-Hirschhorn Syndrome."
    supports: SUPPORT
    snippet: "The most effective ASM was levetiracetam. Although WHS-associated epilepsy is intractable with frequent SE occurrence during infancy, improvement in seizure control is expected with age. Levetiracetam may be a novel ASM for WHS."
    explanation: This study found levetiracetam to be the most effective antiseizure medication for Wolf-Hirschhorn syndrome.
  - reference: PMID:41303083
    reference_title: "Epilepsy in Wolf-Hirschhorn Syndrome: Clinical Insights from a Pediatric Cohort and a Review of the Literature."
    supports: PARTIAL
    snippet: "Valproic acid and levetiracetam were the most commonly used treatments."
    explanation: This cohort study confirms that levetiracetam is one of the most commonly used antiseizure medications for WHS.
- name: Seizure Management with Valproic Acid
  description: Valproic acid is commonly used for epilepsy management in Wolf-Hirschhorn syndrome.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: valproic acid
      term:
        id: CHEBI:39867
        label: valproic acid
  evidence:
  - reference: PMID:41303083
    reference_title: "Epilepsy in Wolf-Hirschhorn Syndrome: Clinical Insights from a Pediatric Cohort and a Review of the Literature."
    supports: SUPPORT
    snippet: "Valproic acid and levetiracetam were the most commonly used treatments."
    explanation: This large cohort study indicates valproic acid is one of the most frequently prescribed antiseizure medications for WHS.
- name: Growth Hormone Therapy
  description: Recombinant human growth hormone therapy for patients with concurrent growth hormone deficiency.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:41017003
    reference_title: "Wolf-Hirschhorn syndrome with growth hormone deficiency: long-term response to RhGH therapy."
    supports: PARTIAL
    snippet: "Across 11 years of rhGH, height improved from ~ - 4.2 to ~ - 1.3 SDS with normalized height velocity and a prolonged but uneventful pubertal course. No major adverse effects were observed. Muscle tone improvement was also noted with treatment initiation."
    explanation: This case report demonstrates long-term efficacy and safety of recombinant human growth hormone therapy in WHS patients with growth hormone deficiency.
- name: Early Aggressive Seizure Management
  description: Early aggressive management using multiple antiseizure medications may be critical to improve neurological prognosis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:41303083
    reference_title: "Epilepsy in Wolf-Hirschhorn Syndrome: Clinical Insights from a Pediatric Cohort and a Review of the Literature."
    supports: SUPPORT
    snippet: "While some patients show improvement with age, early aggressive management using appropriate ASMs may be critical to improve neurological prognosis."
    explanation: This study suggests early aggressive seizure management may improve long-term neurological outcomes in WHS.
- name: Multidisciplinary Rehabilitation Therapy
  description: >
    Multidisciplinary rehabilitation including physical therapy, speech and
    communication therapy, sign language, and occupational therapy is the
    standard of care to address the developmental delay, hypotonia, and
    motor/communication impairments seen in WHS.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  evidence:
  - reference: PMID:20301362
    reference_title: "Wolf-Hirschhorn Syndrome – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment includes: rehabilitation, speech/communication therapy and sign language"
    explanation: GeneReviews lists rehabilitation and speech/communication therapy as core management for WHS.
- name: Feeding Support
  description: >
    Special feeding techniques, gavage feeding, and gastrostomy placement
    are recommended for the feeding difficulties common in WHS, which
    contribute to postnatal growth deficiency.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:20301362
    reference_title: "Wolf-Hirschhorn Syndrome – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "special feeding techniques, gavage feeding, and/or gastrostomy for feeding difficulties"
    explanation: GeneReviews recommends graduated feeding support for the WHS feeding-difficulty phenotype.
- name: Genetic Counseling
  description: >
    Genetic counseling and parental karyotyping are recommended for families
    of affected individuals because ~40-45% of WHS deletions arise from
    unbalanced parental translocations that confer recurrence risk.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:20301362
    reference_title: "Wolf-Hirschhorn Syndrome – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Risks to family members depend on the mechanism of origin of the deletion. Prenatal testing is possible for families in which one parent is known to be a carrier of a chromosome rearrangement involving 4p16.3."
    explanation: GeneReviews establishes the indication for genetic counseling and prenatal testing in WHS families.

📚

References & Deep Research

Deep Research

Falcon ▸

Wolf–Hirschhorn syndrome (WHS): Disease Characteristics Research Report

Edison Scientific Literature 46 citations 2026-04-26T20:22:58.757876

Wolf–Hirschhorn syndrome (WHS): Disease Characteristics Research Report

Target disease: Wolf–Hirschhorn syndrome (genetic contiguous gene deletion disorder; distal 4p deletion). (nevado2020internationalmeetingon pages 3-4, zollino2008onthenosology pages 1-2)

Executive summary (current understanding)

Wolf–Hirschhorn syndrome (WHS) is a contiguous gene deletion syndrome caused by loss of genetic material from the distal short arm of chromosome 4 (4p16.3). It is clinically characterized by a recognizable core phenotype comprising typical craniofacial dysmorphism (“Greek warrior helmet” gestalt), prenatal/postnatal growth deficiency, developmental delay/intellectual disability, and seizures/EEG abnormalities. (nevado2020internationalmeetingon pages 3-4, berrocoso2020copingwithwolfhirschhorna pages 1-2, zollino2008onthenosology pages 1-2)

Recent large-cohort work (Spain/Latin America, n=140; collected 2013–2023) underscores that epilepsy is highly prevalent (92%), begins in infancy (mean onset ~9.8 months), and is frequently severe (status epilepticus 58.4%), with substantial treatment burden (polytherapy common). (blancolago2025epilepsyinwolf–hirschhorn pages 2-4, blancolago2025epilepsyinwolf–hirschhorn pages 1-2)

A major mechanistic advance over the last decade is the refinement of a terminal 4p seizure susceptibility region to an ~197 kb interval near the telomere (hg19/GRCh37 chr4:367,691–564,593), containing PIGG and ZNF721 (and ABCA11P), suggesting that seizure risk is driven by haploinsufficiency of telomeric genes beyond the historically emphasized LETM1 region in at least some individuals. (ho2016chromosomalmicroarraytesting pages 1-1, ho2016chromosomalmicroarraytesting media f15f4c0a)

1. Disease information

1.1 Definition/overview

WHS is a chromosomal disorder caused by distal 4p deletions (usually 4p16.3), producing a multisystem developmental syndrome with characteristic facial features, growth delay, intellectual disability/developmental delay, and seizures. (nevado2020internationalmeetingon pages 3-4, zollino2008onthenosology pages 1-2)

1.2 Key identifiers

OMIM: #194190 (explicitly stated in WHS nosology/meeting proceedings). (nevado2020internationalmeetingon pages 2-2)
MONDO / MeSH / ICD-10 / ICD-11 / Orphanet ORPHAcode: Not retrievable from the tool-accessible full-text corpus in this run. (see Limitations).

1.3 Common synonyms / alternative names

“4p- syndrome”, “deletion 4p”, “terminal 4p deletion” (terminology used across prenatal and clinical genetics literature). (sifakis2012prenataldiagnosisof pages 1-2, nevado2020internationalmeetingon pages 3-4)

1.4 Source type (individual vs aggregated)

Evidence in this report derives from: - Aggregated cohorts and registries (e.g., epidemiology cohort n=159; epilepsy cohort n=140; prenatal cohort n=18). (shannon2001anepidemiologicalstudy pages 1-2, blancolago2025epilepsyinwolf–hirschhorn pages 2-4, simonini2022prenatalsonographicfindings pages 1-2) - Curated clinical genetics guidance (clinical utility gene card). (battaglia2011clinicalutilitygene pages 1-2) - Model organism and developmental biology studies/reviews supporting mechanistic hypotheses. (, )

2. Etiology

2.1 Disease causal factors

Primary cause: hemizygous deletion of the distal short arm of chromosome 4 (4p16.3), with variable deletion size and complexity, producing a contiguous gene haploinsufficiency syndrome. (zollino2008onthenosology pages 1-2, nevado2020internationalmeetingon pages 3-4)

Rearrangement classes reported include: - terminal deletions (most common), - interstitial 4p deletions, - unbalanced translocations (including recurrent 4p;8p events), - ring chromosome 4, - inverted duplications/complex rearrangements. (ho2016chromosomalmicroarraytesting pages 1-1, nevado2020internationalmeetingon pages 4-4, simonini2022prenatalsonographicfindings pages 5-7)

2.2 Risk factors

Genetic risk factors: Presence of a parental balanced translocation involving 4p can raise recurrence risk for offspring with an unbalanced rearrangement; thus parental cytogenetic testing is relevant for counseling. (simonini2022prenatalsonographicfindings pages 5-7, xing2018prenataldiagnosisof pages 5-7)

Environmental risk factors: Not supported in the retrieved evidence; WHS is primarily genetic due to structural chromosome abnormalities. (nevado2020internationalmeetingon pages 3-4, zollino2008onthenosology pages 1-2)

2.3 Protective factors

No validated genetic or environmental protective factors were identified in the retrieved literature.

2.4 Gene–environment interactions

No WHS-specific gene–environment interactions were identified in the retrieved literature.

3. Phenotypes (clinical spectrum)

3.1 Core phenotype (postnatal)

The consensus “core WHS phenotype” includes typical facial dysmorphism, growth delay, intellectual disability/developmental delay, and seizures (or EEG abnormalities). (nevado2020internationalmeetingon pages 3-4)

A large cohort (n=140) quantified high frequencies of major features: - Psychomotor developmental delay: ~98.9% - Craniofacial features: ~97.8% - Hypotonia: ~89% - IUGR/postnatal growth restriction: ~94.2% - Cardiac defects: ~44.5% - Renal/urological anomalies: ~53% (these are cohort-derived rates reported in the epilepsy-focused cohort paper). (blancolago2025epilepsyinwolf–hirschhorn pages 1-2)

3.2 Epilepsy phenotype (key quantitative data)

In the same n=140 cohort, epilepsy burden was high and early-onset: - Epilepsy prevalence: 92% (126/137) - Mean seizure onset: 9.8 months (range 3 days–36 months) - Seizure types (proportions): generalized tonic-clonic 55.9%, absence/atypical absence 51.8%, focal 26.9%, tonic 24.3%, myoclonic 20.4%, epileptic spasms 12.4% - Status epilepticus: 58.4% - Febrile-triggered seizures: 68.6% - Treatment burden: 85.9% treated with antiseizure medications; 42.2% had used ≥3 ASMs; commonly used ASMs were valproic acid and levetiracetam - Genotype–phenotype: larger deletions (>9 Mb) associated with more severe epilepsy and poorer developmental outcomes (pediatric cohort with standardized caregiver questionnaires). (blancolago2025epilepsyinwolf–hirschhorn pages 2-4, blancolago2025epilepsyinwolf–hirschhorn pages 1-2)

Suggested HPO terms (examples): - Seizures HP:0001250; Epileptic spasms HP:0011097; Status epilepticus HP:0002133; Febrile seizures HP:0002373; Developmental delay HP:0001263; Intellectual disability HP:0001249; Hypotonia HP:0001252; Intrauterine growth restriction HP:0001511; Failure to thrive HP:0001508; Microcephaly HP:0000252; Congenital heart defect HP:0001627; Renal anomaly HP:0000077.

3.3 Prenatal phenotype (ultrasound; frequencies)

In a retrospective prenatal cohort of 18 confirmed WHS cases (3 tertiary centers in Germany), the most frequent ultrasound findings were: - Facial abnormalities: 94.4% (17/18) - Symmetric IUGR: 83.3% (15/18) - Microcephaly: 72.2% (13/18) - Cardiac anomalies: 50.0% (9/18) A particularly characteristic combination was microcephaly + hypoplastic nasal bone; growth restriction was present in all fetuses assessed after 20 weeks. (simonini2022prenatalsonographicfindings pages 1-2, simonini2022prenatalsonographicfindings pages 5-7)

A broader prenatal review (10 new + 37 literature cases) reported severe IUGR 97.7% and typical facial appearance 82.9%, with cardiac malformations 29.8% and renal hypoplasia 36.2%. (xing2018prenataldiagnosisof pages 1-2)

Suggested prenatal HPO terms (examples): IUGR HP:0001511; Hypoplastic nasal bone HP:0012745; Abnormal facial shape HP:0001999; Micrognathia HP:0000347.

3.4 Quality of life impact

A study of 22 Spanish caregivers evaluated psychosocial profile and caregiver quality of life (QoL) and found that the syndrome’s severe, lifelong care needs (growth issues, seizures, developmental disability) can impact parental QoL; problem-focused coping and social support were associated with improved psychological QoL. (berrocoso2020copingwithwolfhirschhorna pages 1-2)

4. Genetic / molecular information

4.1 Causal genomic lesion and critical regions

WHS is caused by deletions of 4p16.3 with broad size variation; meeting proceedings and genotype–phenotype analyses emphasize variability from <2 Mb up to ~30 Mb or more. (nevado2020internationalmeetingon pages 3-4)

Historically defined WHS “critical regions” include: - WHSCR: a ~165 kb interval ~2 Mb from the telomere, containing WHSC1/NSD2 and WHSC2/NELFA. (nevado2020internationalmeetingon pages 4-4) - WHSCR-2: an adjacent 300–600 kb interval including LETM1 (a long-discussed seizure candidate) and part of WHSC1/NSD2. (ho2016chromosomalmicroarraytesting pages 1-1)

4.2 Genotype–phenotype correlations (deletion size)

Multiple sources define broad severity bands: - Mild: deletions ≤3.5 Mb - Typical/classic: ~5–18 Mb - Severe: ~22–25 Mb or more (Prenatal and postnatal sources concordantly report this pattern). (zollino2008onthenosology pages 1-2, luo2023prenataldiagnosisand pages 2-3, simonini2022prenatalsonographicfindings pages 5-7)

4.3 Seizure susceptibility region (recent mapping)

A chromosomal microarray mapping study (n=48) identified a strong association between interstitial deletions that exclude the distal terminal segment and absence of seizures, and refined a terminal seizure susceptibility region to ~197 kb beginning ~368 kb from the 4p terminus. (ho2016chromosomalmicroarraytesting pages 1-1)

Figure-based coordinates and genes in this interval (hg19/GRCh37 chr4:367,691–564,593) include PIGG and ZNF721 (and ABCA11P). (ho2016chromosomalmicroarraytesting media f15f4c0a)

4.4 Inheritance and origin

WHS rearrangements are often de novo, but familial recurrence can occur via parental balanced translocations. In a UK epidemiologic cohort (n=159): 72.3% de novo deletions, 20.1% translocations, 7.5% other rearrangements. (shannon2001anepidemiologicalstudy pages 1-2)

In the prenatal literature, approximate etiologic fractions are described as ~55% de novo deletions, ~40–45% unbalanced translocations, and ~5% complex rearrangements. (simonini2022prenatalsonographicfindings pages 5-7)

4.5 Epigenetics / modifiers

Phenotypic severity is not strictly linear with deletion size; meeting proceedings discuss that LETM1 haploinsufficiency alone is not sufficient for seizures, implying additional telomeric dosage-sensitive genes and/or modifier effects. (nevado2020internationalmeetingon pages 4-5)

5. Environmental information

No WHS-specific environmental toxins, lifestyle risk factors, or infectious triggers causing WHS were identified in retrieved evidence. WHS is primarily a structural genomic disorder. (nevado2020internationalmeetingon pages 3-4, zollino2008onthenosology pages 1-2)

6. Mechanism / pathophysiology

6.1 Causal chain (conceptual)

Upstream trigger: hemizygous deletion of distal 4p (4p16.3) → haploinsufficiency of multiple developmental genes (including NSD2/WHSC1, NELFA/WHSC2, LETM1, and telomeric genes such as PIGG/ZNF721) → disruption of transcriptional regulation, neuronal excitability balance and developmental programs → downstream neurodevelopmental impairment, growth delay, craniofacial malformations, congenital anomalies, and epilepsy (often early-onset and severe). (zollino2008onthenosology pages 1-2, ho2016chromosomalmicroarraytesting pages 1-1, nevado2020internationalmeetingon pages 4-5)

6.2 Seizure biology (regional genetics)

The CMA mapping work supports a model in which deletion of a small terminal region can be sufficient for seizure susceptibility in WHS, refining the mechanistic focus beyond LETM1 alone. (ho2016chromosomalmicroarraytesting pages 1-1, ho2016chromosomalmicroarraytesting media f15f4c0a)

6.3 Developmental mechanisms: neural crest hypothesis (model-organism evidence)

A Xenopus-focused primary study supports the hypothesis that WHS craniofacial and related defects may arise from perturbation of cranial neural crest biology: WHS-associated genes (whsc1, whsc2, letm1, tacc3) show enrichment in migratory neural crest and influence craniofacial patterning/cartilage formation and neural crest motility when depleted. ()

Suggested GO Biological Process terms (examples): - cranial neural crest cell migration (GO:0002302), - regulation of transcription, DNA-templated (GO:0006355), - nervous system development (GO:0007399), - synaptic signaling (GO:0099536), - mitochondrial calcium ion homeostasis (candidate for LETM1-related mechanisms).

Suggested CL cell-type terms (examples): - neural crest cell (CL:0000134), - excitatory neuron (CL:0000127), - inhibitory interneuron (CL:0000099).

7. Anatomical structures affected

Based on the multisystem phenotype described in cohorts: - Nervous system: epilepsy, developmental delay (UBERON:0001016 “nervous system”; brain UBERON:0000955). (blancolago2025epilepsyinwolf–hirschhorn pages 2-4) - Craniofacial structures: characteristic facial gestalt; craniofacial developmental defects (UBERON:0001136 “facial skeleton”). (berrocoso2020copingwithwolfhirschhorna pages 1-2) - Cardiovascular system: congenital heart defects (~44.5% in a large cohort; 50% in prenatal series). (blancolago2025epilepsyinwolf–hirschhorn pages 1-2, simonini2022prenatalsonographicfindings pages 1-2) - Urinary system/kidney: renal/urologic anomalies (~53% in large cohort; renal hypoplasia often reported prenatally). (blancolago2025epilepsyinwolf–hirschhorn pages 1-2, xing2018prenataldiagnosisof pages 1-2)

8. Temporal development

Onset: congenital; many features are prenatal (IUGR, microcephaly, facial anomalies) and postnatal developmental delay is universal/near-universal in cohorts. (simonini2022prenatalsonographicfindings pages 1-2, blancolago2025epilepsyinwolf–hirschhorn pages 1-2)
Epilepsy onset: typically within the first year; mean onset ~9.8 months. (blancolago2025epilepsyinwolf–hirschhorn pages 2-4)
Course: high early-childhood morbidity and mortality; survival improves after age 2, with some individuals surviving into adulthood (documented up to mid-30s in UK cohort, and to 55 years in adult natural history series). (shannon2001anepidemiologicalstudy pages 1-2, shannon2001anepidemiologicalstudy pages 1-1)

9. Inheritance and population

9.1 Epidemiology

Minimum UK birth incidence (1989–1998): 1 in 95,896. (shannon2001anepidemiologicalstudy pages 1-2, shannon2001anepidemiologicalstudy pages 1-1)
Commonly cited incidence/prevalence in clinical literature: ~1/20,000–1/50,000 births, with female predominance ~2:1. (berrocoso2020copingwithwolfhirschhorna pages 1-2, nevado2025clinicianbasedfunctionalscoring pages 1-2)

9.2 Inheritance pattern

WHS is typically sporadic/de novo as a chromosomal deletion syndrome; familial recurrence risk depends on parental chromosomal rearrangements (balanced translocation carriers). (shannon2001anepidemiologicalstudy pages 1-2, simonini2022prenatalsonographicfindings pages 5-7)

10. Diagnostics

10.1 Clinical suspicion

Prenatal: symmetric IUGR + microcephaly + hypoplastic nasal bone + facial anomalies should raise suspicion. (simonini2022prenatalsonographicfindings pages 1-2)
Postnatal: characteristic facial gestalt + growth restriction + neurodevelopmental delay + seizures/EEG abnormalities. (nevado2020internationalmeetingon pages 3-4, berrocoso2020copingwithwolfhirschhorna pages 1-2)

10.2 Genetic testing strategy (real-world implementation)

Chromosomal microarray (CMA) is highlighted as the method of choice for diagnosis, particularly to detect small deletions (<3 Mb) and complex rearrangements. (simonini2022prenatalsonographicfindings pages 1-2, simonini2022prenatalsonographicfindings pages 5-7)
Routine karyotype detection ~50–60%; FISH sensitivity ~95% in prenatal review. (simonini2022prenatalsonographicfindings pages 1-2)
Clinical utility gene card: appropriately designed FISH or genomic microarray targeting at least portions of LETM1 and WHSC1 should yield >99% clinical sensitivity; standard chromosome studies may have only ~50–60% sensitivity and can miss microdeletions. (battaglia2011clinicalutilitygene pages 1-2)

10.3 Differential diagnosis

A formal differential diagnosis list was not available in retrieved full texts. In practice, WHS overlaps with other chromosomal deletion syndromes presenting with growth restriction, dysmorphism, and epilepsy; confirmation requires molecular cytogenetics (CMA/FISH/karyotype). (battaglia2011clinicalutilitygene pages 1-2, nevado2020internationalmeetingon pages 3-4)

11. Outcomes / prognosis

11.1 Survival and mortality (key statistics)

In the UK epidemiologic cohort: - Infant mortality: 17.4% (23/132) - Two-year mortality: 21% (28/132) - Timing: 63.9% of deaths in the first year; 77.8% within the first two years - Deletion size prognostic factor: large deletions had 51.5% deaths vs 9.7% for small deletions; adjusted OR 5.7 (95% CI 1.7–19.9) (published Oct 2001). (shannon2001anepidemiologicalstudy pages 3-4)

Among deaths with known cause (n=32): - lower respiratory tract infection 25% (8/32), - multiple congenital anomalies 15.6% (5/32), - sudden unexplained death 15.6% (5/32), - congenital heart disease 15.6% (5/32). (published Oct 2001). (shannon2001anepidemiologicalstudy pages 4-5)

11.2 Prognostic factors

Deletion size and complexity (large deletions, complex rearrangements). (shannon2001anepidemiologicalstudy pages 3-4)
Epilepsy severity and seizure pattern, emphasized as major determinants of neurodevelopmental outcome. (nevado2020internationalmeetingon pages 3-4, blancolago2025epilepsyinwolf–hirschhorn pages 2-4)

12. Treatment

12.1 Pharmacotherapy (epilepsy)

In a large WHS cohort, commonly used antiseizure medications were valproic acid and levetiracetam, and many individuals required polytherapy; status epilepticus was frequent and likely contributes to developmental burden. (blancolago2025epilepsyinwolf–hirschhorn pages 1-2, blancolago2025epilepsyinwolf–hirschhorn pages 2-4)

Suggested MAXO terms (examples): - antiseizure therapy (MAXO:0000474), - status epilepticus management (MAXO term to map under emergency seizure management), - chromosomal microarray analysis (diagnostic procedure term), - genetic counseling (MAXO:0000072), - early intervention therapy / neurodevelopmental therapy (MAXO mapping under rehabilitation).

12.2 Supportive / rehabilitative care

Consensus and cohort interpretations emphasize multidisciplinary management (developmental therapies, monitoring for comorbidities such as cardiac/renal problems, and family support). (berrocoso2020copingwithwolfhirschhorna pages 1-2, shannon2001anepidemiologicalstudy pages 6-6)

12.3 Experimental / trials

A precise ClinicalTrials.gov condition search for “Wolf-Hirschhorn syndrome” did not retrieve disease-specific interventional trials in this tool run; earlier broad “WHS” queries primarily matched unrelated acronym uses (e.g., Women’s Health Study). (nevado2020internationalmeetingon pages 11-11)

13. Prevention

Primary “prevention” for WHS is reproductive/genetic: - Genetic counseling for affected families, - Prenatal diagnosis using ultrasound plus confirmatory CMA/karyotype/FISH, - Parental karyotyping to detect balanced translocations that elevate recurrence risk. (simonini2022prenatalsonographicfindings pages 5-7, battaglia2011clinicalutilitygene pages 1-2)

14. Other species / natural disease

No naturally occurring veterinary analogs were identified in retrieved evidence.

15. Model organisms

Mechanistic studies in vertebrate models support developmental hypotheses: - Xenopus laevis: WHS-associated genes are enriched in migratory neural crest cells; depletion affects craniofacial development and neural crest motility. () - Additional vertebrate resources were retrieved for zebrafish WHSC1/NSD2 homolog biology, supporting in vivo functional studies of WHS candidate genes. ()

Recent developments (prioritizing 2023–2024 where available)

2024: A familial terminal 4p16.3 microdeletion not causing classical WHS supports refinement of critical regions and highlights interpretive complexity for small telomeric CNVs. (Osundiji 2024; publication date Nov 2024; Chromosome Research). (osundiji2024afamilialchromosome pages 7-8)
2024: Basic mechanistic enzymology work expanded the substrate landscape of NSD2 (WHSC1), relevant to understanding pleiotropy of NSD2 haploinsufficiency in development and disease (not WHS-specific clinical study, but mechanistically relevant). (Weirich 2024; Communications Biology; Jun 2024). ()

Key quantitative findings (quick reference)

Topic	Key findings (with numbers)	Source (first author year)	URL/DOI
Birth incidence / prevalence and sex ratio	Minimum UK birth incidence 1 in 95,896; broader literature estimates 1 in 50,000 births and ~1 in 20,000–1 in 50,000 births; female predominance about 2:1; 2025 WHS cohort female proportion 67.9% (Blanco-Lago cohort) (shannon2001anepidemiologicalstudy pages 1-2, shannon2001anepidemiologicalstudy pages 1-1, berrocoso2020copingwithwolfhirschhorna pages 1-2, blancolago2025epilepsyinwolf–hirschhorn pages 2-4)	Shannon 2001; Berrocoso 2020; Corrêa 2018; Blanco-Lago 2025	https://doi.org/10.1136/jmg.38.10.674; https://doi.org/10.1186/s13023-020-01476-8; https://doi.org/10.1155/2018/5436187; https://doi.org/10.3390/jcm14228044
Mortality rates and leading causes of death	Among 132 live births, infant mortality 17.4% (23/132) and 2-year mortality 21% (28/132); 63.9% of deaths in first year and 77.8% within first 2 years; large deletions had 51.5% deaths vs 9.7% for small deletions (age-adjusted OR 5.7, 95% CI 1.7–19.9); leading causes among known causes: lower respiratory tract infection 25% (8/32), multiple congenital anomalies 15.6% (5/32), sudden unexplained death 15.6% (5/32), congenital heart disease 15.6% (5/32) (shannon2001anepidemiologicalstudy pages 3-4, shannon2001anepidemiologicalstudy pages 4-5, shannon2001anepidemiologicalstudy pages 5-6)	Shannon 2001	https://doi.org/10.1136/jmg.38.10.674
Epilepsy burden	Epilepsy in 92% (126/137); mean seizure onset 9.8 months (range 3 days–36 months), typically before 12 months; seizure frequencies: generalized tonic-clonic 55.9%, absence/atypical absence 51.8%, focal 26.9%, tonic 24.3%, myoclonic 20.4%, epileptic spasms 12.4%; status epilepticus 58.4%; febrile-triggered seizures 68.6%; 85.9% on ASMs, 42.2% had used ≥3 ASMs; common ASMs valproic acid and levetiracetam; larger deletions (>9 Mb) associated with more severe epilepsy/poorer outcomes (blancolago2025epilepsyinwolf–hirschhorn pages 2-4, blancolago2025epilepsyinwolf–hirschhorn pages 1-2, blancolago2025epilepsyinwolf–hirschhorn pages 9-11)	Blanco-Lago 2025	https://doi.org/10.3390/jcm14228044
Prenatal ultrasound frequencies and diagnostic recommendations	In 18 confirmed prenatal cases: facial abnormalities 94.4% (17/18), symmetric IUGR 83.3% (15/18), microcephaly 72.2% (13/18), cardiac anomalies 50.0% (9/18); growth restriction present in all fetuses examined after 20 weeks; characteristic combination: microcephaly + hypoplastic nasal bone; pooled review data: severe IUGR 97.7% and typical facial appearance 82.9%, cardiac malformations 29.8%; CMA/SNP-array strongly recommended when WHS is suspected prenatally (simonini2022prenatalsonographicfindings pages 1-2, simonini2022prenatalsonographicfindings pages 5-7, xing2018prenataldiagnosisof pages 1-2, xing2018prenataldiagnosisof pages 3-5)	Simonini 2022; Xing 2018	https://doi.org/10.1186/s12884-022-04665-4; https://doi.org/10.1007/s00404-018-4798-1
Genetic testing sensitivity guidance	Routine karyotype detects ~50–60% of cases; FISH sensitivity reported ~95%; gene card states appropriately designed FISH or genomic microarray targeting LETM1/WHSC1 region should provide >99% clinical sensitivity; CMA is current method of choice because small deletions (<3 Mb) and complex rearrangements may be missed by karyotype/FISH; parental studies recommended when translocation suspected (battaglia2011clinicalutilitygene pages 1-2, simonini2022prenatalsonographicfindings pages 1-2, simonini2022prenatalsonographicfindings pages 5-7, xing2018prenataldiagnosisof pages 5-7)	Battaglia 2011; Simonini 2022	https://doi.org/10.1038/ejhg.2010.186; https://doi.org/10.1186/s12884-022-04665-4
Seizure susceptibility region coordinates / genes	CMA study mapped terminal seizure susceptibility region to ~197 kb starting ~368 kb from 4p terminus; figure-based coordinates hg19/GRCh37 chr4:367,691–564,593; region contains PIGG, ZNF721, and pseudogene ABCA11P; lack of inclusion of distal terminal 751 kb associated with absence of seizures in several interstitial deletion cases (ho2016chromosomalmicroarraytesting pages 1-1, ho2016chromosomalmicroarraytesting media 365127d8, ho2016chromosomalmicroarraytesting media f15f4c0a)	Ho 2016	https://doi.org/10.1136/jmedgenet-2015-103626

Table: This table compiles the most implementation-relevant quantitative findings for Wolf-Hirschhorn syndrome, including epidemiology, mortality, epilepsy burden, prenatal detection, testing performance, and the mapped seizure-susceptibility region. It is designed for quick reference in clinical or knowledge-base curation workflows.

Visual evidence (genotype–seizure mapping)

The seizure susceptibility region on terminal 4p and the gene content of the refined ~197 kb interval are illustrated in the CMA mapping figures (Figure 2/3) from Ho et al. 2016. (ho2016chromosomalmicroarraytesting media 365127d8, ho2016chromosomalmicroarraytesting media f15f4c0a)

Limitations of this report (tooling constraints)

The tool-accessible corpus did not yield primary sources explicitly listing MONDO ID, Orphanet ORPHAcode, MeSH descriptor ID, or ICD-10/ICD-11 codes for WHS; therefore these identifiers are not asserted here.
Several clinically important areas (formal differential diagnosis lists; standardized QoL instruments for affected individuals) were not available in retrieved texts and may require additional targeted retrieval beyond the current run.

References

(nevado2020internationalmeetingon pages 3-4): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.
(zollino2008onthenosology pages 1-2): Marcella Zollino, Marina Murdolo, Giuseppe Marangi, Vanna Pecile, Cinzia Galasso, Laura Mazzanti, and Giovanni Neri. On the nosology and pathogenesis of wolf–hirschhorn syndrome: genotype–phenotype correlation analysis of 80 patients and literature review. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 148C:257-269, Nov 2008. URL: https://doi.org/10.1002/ajmg.c.30190, doi:10.1002/ajmg.c.30190. This article has 216 citations.
(berrocoso2020copingwithwolfhirschhorna pages 1-2): Sarah Berrocoso, Imanol Amayra, Esther Lázaro, Oscar Martínez, Juan Francisco López-Paz, Maitane García, Manuel Pérez, Mohammad Al-Rashaida, Alicia Aurora Rodríguez, Paula Maria Luna, Paula Pérez-Núñez, Raquel Blanco, and Julián Nevado. Coping with wolf-hirschhorn syndrome: quality of life and psychosocial features of family carers. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01476-8, doi:10.1186/s13023-020-01476-8. This article has 29 citations and is from a peer-reviewed journal.
(blancolago2025epilepsyinwolf–hirschhorn pages 2-4): Raquel Blanco-Lago, Ignacio Málaga, Jair Antonio Tenorio-Castaño, Nelly Álvarez-Álvarez, Pablo Lapunzina, and Julián Nevado. Epilepsy in wolf–hirschhorn syndrome: clinical insights from a pediatric cohort and a review of the literature. Journal of Clinical Medicine, 14:8044, Nov 2025. URL: https://doi.org/10.3390/jcm14228044, doi:10.3390/jcm14228044. This article has 0 citations.
(blancolago2025epilepsyinwolf–hirschhorn pages 1-2): Raquel Blanco-Lago, Ignacio Málaga, Jair Antonio Tenorio-Castaño, Nelly Álvarez-Álvarez, Pablo Lapunzina, and Julián Nevado. Epilepsy in wolf–hirschhorn syndrome: clinical insights from a pediatric cohort and a review of the literature. Journal of Clinical Medicine, 14:8044, Nov 2025. URL: https://doi.org/10.3390/jcm14228044, doi:10.3390/jcm14228044. This article has 0 citations.
(ho2016chromosomalmicroarraytesting pages 1-1): Karen S Ho, Sarah T South, Amanda Lortz, Charles H Hensel, Mallory R Sdano, Rena J Vanzo, Megan M Martin, Andreas Peiffer, Christophe G Lambert, Amy Calhoun, John C Carey, and Agatino Battaglia. Chromosomal microarray testing identifies a 4p terminal region associated with seizures in wolf–hirschhorn syndrome. Journal of Medical Genetics, 53:256-263, Jan 2016. URL: https://doi.org/10.1136/jmedgenet-2015-103626, doi:10.1136/jmedgenet-2015-103626. This article has 59 citations and is from a domain leading peer-reviewed journal.
(ho2016chromosomalmicroarraytesting media f15f4c0a): Karen S Ho, Sarah T South, Amanda Lortz, Charles H Hensel, Mallory R Sdano, Rena J Vanzo, Megan M Martin, Andreas Peiffer, Christophe G Lambert, Amy Calhoun, John C Carey, and Agatino Battaglia. Chromosomal microarray testing identifies a 4p terminal region associated with seizures in wolf–hirschhorn syndrome. Journal of Medical Genetics, 53:256-263, Jan 2016. URL: https://doi.org/10.1136/jmedgenet-2015-103626, doi:10.1136/jmedgenet-2015-103626. This article has 59 citations and is from a domain leading peer-reviewed journal.
(nevado2020internationalmeetingon pages 2-2): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.
(sifakis2012prenataldiagnosisof pages 1-2): Stavros Sifakis, Emmanouil Manolakos, Annalisa Vetro, Dimitra Kappou, Panagiotis Peitsidis, Maria Kontodiou, Antonios Garas, Nikolaos Vrachnis, Anastasia Konstandinidou, Orsetta Zuffardi, Sandro Orru, and Ioannis Papoulidis. Prenatal diagnosis of wolf-hirschhorn syndrome confirmed by comparative genomic hybridization array: report of two cases and review of the literature. Molecular Cytogenetics, 5:12-12, Feb 2012. URL: https://doi.org/10.1186/1755-8166-5-12, doi:10.1186/1755-8166-5-12. This article has 35 citations and is from a peer-reviewed journal.
(shannon2001anepidemiologicalstudy pages 1-2): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.
(simonini2022prenatalsonographicfindings pages 1-2): Corinna Simonini, Markus Hoopmann, Karl Oliver Kagan, Torsten Schröder, Ulrich Gembruch, and Annegret Geipel. Prenatal sonographic findings in confirmed cases of wolf-hirschhorn syndrome. BMC Pregnancy and Childbirth, Apr 2022. URL: https://doi.org/10.1186/s12884-022-04665-4, doi:10.1186/s12884-022-04665-4. This article has 13 citations and is from a peer-reviewed journal.
(battaglia2011clinicalutilitygene pages 1-2): Agatino Battaglia, Sarah South, and John C Carey. Clinical utility gene card for: wolf–hirschhorn (4p-) syndrome. European Journal of Human Genetics, 19:-, Apr 2011. URL: https://doi.org/10.1038/ejhg.2010.186, doi:10.1038/ejhg.2010.186. This article has 23 citations and is from a domain leading peer-reviewed journal.
(nevado2020internationalmeetingon pages 4-4): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.
(simonini2022prenatalsonographicfindings pages 5-7): Corinna Simonini, Markus Hoopmann, Karl Oliver Kagan, Torsten Schröder, Ulrich Gembruch, and Annegret Geipel. Prenatal sonographic findings in confirmed cases of wolf-hirschhorn syndrome. BMC Pregnancy and Childbirth, Apr 2022. URL: https://doi.org/10.1186/s12884-022-04665-4, doi:10.1186/s12884-022-04665-4. This article has 13 citations and is from a peer-reviewed journal.
(xing2018prenataldiagnosisof pages 5-7): Ya Xing, Jimmy Lloyd Holder, Yong Liu, Meizhen Yuan, Qi Sun, Xiaoxing Qu, Linbei Deng, Jia Zhou, Yingjun Yang, Ming Guo, Sau-Wai Cheung, and Luming Sun. Prenatal diagnosis of wolf–hirschhorn syndrome: from ultrasound findings, diagnostic technology to genetic counseling. Archives of Gynecology and Obstetrics, 298:289-295, May 2018. URL: https://doi.org/10.1007/s00404-018-4798-1, doi:10.1007/s00404-018-4798-1. This article has 36 citations and is from a peer-reviewed journal.
(xing2018prenataldiagnosisof pages 1-2): Ya Xing, Jimmy Lloyd Holder, Yong Liu, Meizhen Yuan, Qi Sun, Xiaoxing Qu, Linbei Deng, Jia Zhou, Yingjun Yang, Ming Guo, Sau-Wai Cheung, and Luming Sun. Prenatal diagnosis of wolf–hirschhorn syndrome: from ultrasound findings, diagnostic technology to genetic counseling. Archives of Gynecology and Obstetrics, 298:289-295, May 2018. URL: https://doi.org/10.1007/s00404-018-4798-1, doi:10.1007/s00404-018-4798-1. This article has 36 citations and is from a peer-reviewed journal.
(luo2023prenataldiagnosisand pages 2-3): H Luo, R Chang, F Liu, and X Gao. Prenatal diagnosis and molecular cytogenetic analyses of a de novo deletion on chromosome 4p16. 3p15. 33. Unknown journal, 2023.
(nevado2020internationalmeetingon pages 4-5): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.
(shannon2001anepidemiologicalstudy pages 1-1): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.
(nevado2025clinicianbasedfunctionalscoring pages 1-2): Julián Nevado, Raquel Blanco-Lago, Cristina Bel-Fenellós, Adolfo Hernández, María A. Mori-Álvarez, Chantal Biencinto-López, Ignacio Málaga, Harry Pachajoa, Elena Mansilla, Fe A. García-Santiago, Pilar Barrúz, Jair A. Tenorio-Castaño, Yolanda Muñoz-GªPorrero, Isabel Vallcorba, and Pablo Lapunzina. Clinician-based functional scoring and genomic insights for prognostic stratification in wolf–hirschhorn syndrome. Genes, 16:820, Jul 2025. URL: https://doi.org/10.3390/genes16070820, doi:10.3390/genes16070820. This article has 1 citations.
(shannon2001anepidemiologicalstudy pages 3-4): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.
(shannon2001anepidemiologicalstudy pages 4-5): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.
(shannon2001anepidemiologicalstudy pages 6-6): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.
(nevado2020internationalmeetingon pages 11-11): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.
(osundiji2024afamilialchromosome pages 7-8): Mayowa Azeez Osundiji, Eva Kahn, and Brendan Lanpher. A familial chromosome 4p16.3 terminal microdeletion that does not cause wolf-hirschhorn (4p-) syndrome. Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology, 32 4:13, Nov 2024. URL: https://doi.org/10.1007/s10577-024-09757-9, doi:10.1007/s10577-024-09757-9. This article has 0 citations.
(shannon2001anepidemiologicalstudy pages 5-6): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.
(blancolago2025epilepsyinwolf–hirschhorn pages 9-11): Raquel Blanco-Lago, Ignacio Málaga, Jair Antonio Tenorio-Castaño, Nelly Álvarez-Álvarez, Pablo Lapunzina, and Julián Nevado. Epilepsy in wolf–hirschhorn syndrome: clinical insights from a pediatric cohort and a review of the literature. Journal of Clinical Medicine, 14:8044, Nov 2025. URL: https://doi.org/10.3390/jcm14228044, doi:10.3390/jcm14228044. This article has 0 citations.
(xing2018prenataldiagnosisof pages 3-5): Ya Xing, Jimmy Lloyd Holder, Yong Liu, Meizhen Yuan, Qi Sun, Xiaoxing Qu, Linbei Deng, Jia Zhou, Yingjun Yang, Ming Guo, Sau-Wai Cheung, and Luming Sun. Prenatal diagnosis of wolf–hirschhorn syndrome: from ultrasound findings, diagnostic technology to genetic counseling. Archives of Gynecology and Obstetrics, 298:289-295, May 2018. URL: https://doi.org/10.1007/s00404-018-4798-1, doi:10.1007/s00404-018-4798-1. This article has 36 citations and is from a peer-reviewed journal.
(ho2016chromosomalmicroarraytesting media 365127d8): Karen S Ho, Sarah T South, Amanda Lortz, Charles H Hensel, Mallory R Sdano, Rena J Vanzo, Megan M Martin, Andreas Peiffer, Christophe G Lambert, Amy Calhoun, John C Carey, and Agatino Battaglia. Chromosomal microarray testing identifies a 4p terminal region associated with seizures in wolf–hirschhorn syndrome. Journal of Medical Genetics, 53:256-263, Jan 2016. URL: https://doi.org/10.1136/jmedgenet-2015-103626, doi:10.1136/jmedgenet-2015-103626. This article has 59 citations and is from a domain leading peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Source YAML

References & Deep Research

Deep Research

Wolf–Hirschhorn syndrome (WHS): Disease Characteristics Research Report

Executive summary (current understanding)

1. Disease information

1.1 Definition/overview

1.2 Key identifiers

1.3 Common synonyms / alternative names

1.4 Source type (individual vs aggregated)

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes (clinical spectrum)

3.1 Core phenotype (postnatal)

3.2 Epilepsy phenotype (key quantitative data)

3.3 Prenatal phenotype (ultrasound; frequencies)

3.4 Quality of life impact

4. Genetic / molecular information

4.1 Causal genomic lesion and critical regions

4.2 Genotype–phenotype correlations (deletion size)

4.3 Seizure susceptibility region (recent mapping)

4.4 Inheritance and origin

4.5 Epigenetics / modifiers

5. Environmental information

6. Mechanism / pathophysiology

6.1 Causal chain (conceptual)

6.2 Seizure biology (regional genetics)

6.3 Developmental mechanisms: neural crest hypothesis (model-organism evidence)

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

9.1 Epidemiology

9.2 Inheritance pattern

10. Diagnostics

10.1 Clinical suspicion

10.2 Genetic testing strategy (real-world implementation)

10.3 Differential diagnosis

11. Outcomes / prognosis

11.1 Survival and mortality (key statistics)

11.2 Prognostic factors

12. Treatment

12.1 Pharmacotherapy (epilepsy)

12.2 Supportive / rehabilitative care

12.3 Experimental / trials

13. Prevention

14. Other species / natural disease

15. Model organisms

Recent developments (prioritizing 2023–2024 where available)

Key quantitative findings (quick reference)

Visual evidence (genotype–seizure mapping)

Limitations of this report (tooling constraints)